var title_f8_52_9024="Normal HIDA scan";
var content_f8_52_9024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F59241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F59241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Normal HIDA scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an example of a normal HIDA scan and shows early filling of the gallbladder at 15 minutes (white arrow) and complete filling by 25 minutes (white arrowhead) indicating a patent cystic duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9024=[""].join("\n");
var outline_f8_52_9024=null;
var title_f8_52_9025="Aceclofenac: International drug information";
var content_f8_52_9025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aceclofenac: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Air-Tal (BE);",
"     </li>",
"     <li>",
"      Airtal (ES, PT);",
"     </li>",
"     <li>",
"      Aital (NL);",
"     </li>",
"     <li>",
"      Barcan (DK, NO, SE);",
"     </li>",
"     <li>",
"      Beofenac (AT, DE, PT);",
"     </li>",
"     <li>",
"      Berlofen (AR);",
"     </li>",
"     <li>",
"      Biofenac (BE, NL);",
"     </li>",
"     <li>",
"      Bristaflam (AR, MX);",
"     </li>",
"     <li>",
"      Falcol (ES);",
"     </li>",
"     <li>",
"      Gerbin (ES);",
"     </li>",
"     <li>",
"      Locomin (CH);",
"     </li>",
"     <li>",
"      Preservex (GB);",
"     </li>",
"     <li>",
"      Proflam (BR, IT);",
"     </li>",
"     <li>",
"      Sanein (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Nonsteroidal Anti-inflammatory Drug",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pain and inflammation in rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 100 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10470 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FC5DC09734-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9025=[""].join("\n");
var outline_f8_52_9025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303275\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977420\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977543\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977419\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821078\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977542\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10470\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10470|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_52_9026="Latissimus dorsi reconstruction";
var content_f8_52_9026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Latissimus dorsi flap reconstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following left mastectomy, breast reconstruction was performed with a tissue expander and a latissimus dorsi flap, followed by an anatomic saline implant. Left panel: preoperative appearance; right panel, postoperative appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jorge de la Pedraja, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9026=[""].join("\n");
var outline_f8_52_9026=null;
var title_f8_52_9027="Sellar mass MRI II";
var content_f8_52_9027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sellar mass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 206px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MRI on the left shows in sagittal view a very large pituitary adenoma elevating the optic chiasm (arrow). The MRI on the right shows a sellar mass of similar size, which has a much brighter signal than the mass on the left (arrow). The reason for the brighter signal could have been hemorrhage into a pituitary adenoma, but in this case was found surgically to be fluid in a craniopharyngioma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter J Snyder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9027=[""].join("\n");
var outline_f8_52_9027=null;
var title_f8_52_9028="Physostigmine: Pediatric drug information";
var content_f8_52_9028=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Physostigmine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40372?source=see_link\">",
"    see \"Physostigmine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/60/33731?source=see_link\">",
"    see \"Physostigmine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1061061\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Anticholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholinergic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cholinergic Agent, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1061056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40372?source=see_link\">",
"      see \"Physostigmine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reversal of toxic anticholinergic effects:",
"     <b>",
"      Note:",
"     </b>",
"     Administer slowly over 5 minutes to prevent respiratory distress and seizures. Continuous infusions of physostigmine should never be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Reserve for life-threatening situations only: I.V.: 0.01-0.03 mg/kg/dose; may repeat after 15-20 minutes to a maximum total dose of 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: I.M., I.V., SubQ: 0.5-2 mg initially, repeat every 20 minutes until response or adverse effect occurs; repeat 1-4 mg every 30-60 minutes as life-threatening symptoms recur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preanesthetic reversal: Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: Give twice the dose, on a weight basis, of the anticholinergic drug (atropine, scopolamine)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as salicylate: 1 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1061065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Infuse slowly I.V. without additional dilution over 5 minutes. Too rapid administration can cause bradycardia and hypersalivation leading to respiratory distress and seizures.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F209720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, fat emulsion 10%, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Ampicillin, epinephrine, famotidine, heparin, hydrocortisone sodium succinate, potassium chloride, tolazoline, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dobutamine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1061064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reverse toxic, life-threatening delirium caused by atropine, diphenhydramine, dimenhydrinate,",
"     <i>",
"      Atropa belladonna",
"     </i>",
"     (deadly nightshade), or jimson weed (",
"     <i>",
"      Datura",
"     </i>",
"     spp)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Physostigmine may be confused with Prostigmin&reg;, pyridostigmine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F209719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Asystole, bradycardia, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Hallucinations, nervousness, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, salivation, stomach pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation, miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, pulmonary edema, respiratory paralysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1061069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to physostigmine or any component; GI or GU obstruction, asthma, diabetes mellitus, gangrene, severe cardiovascular disease; patients receiving depolarizing neuromuscular blockers (eg, succinylcholine)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1061055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with epilepsy, narrow-angle glaucoma, marked vagotonia, parkinsonism, bradycardia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1061054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Because physostigmine has the potential for producing severe adverse effects, (ie, seizures, bradycardia), routine use as an antidote is controversial. Patients must have a normal QRS interval, as measured by ECG, in order to receive; use caution in poisoning with agents known to prolong intraventricular conduction. Atropine should be readily available to treat severe adverse effects. Injection contains benzyl alcohol and bisulfite which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites; use injection with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, medications used as antidotes should take into consideration the health and prognosis of the mother.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1061060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, respiratory rate, ECG",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1061053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits destruction of acetylcholine by acetylcholinesterase which prolongs the central and peripheral effects of acetylcholine",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1061067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Within 3-8 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 30 minutes to 1 hour",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1061068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed throughout the body; crosses into the CNS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Via hydrolysis by cholinesterases",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12703 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9028=[""].join("\n");
var outline_f8_52_9028=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061061\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061056\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209674\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209658\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061065\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209720\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061064\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209722\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209719\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061069\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061055\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061054\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299877\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209667\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823806\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061060\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061053\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061067\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1061068\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12703\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12703|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40372?source=related_link\">",
"      Physostigmine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/60/33731?source=related_link\">",
"      Physostigmine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_52_9029="Laparoendoscopic single-site (single port) surgery";
var content_f8_52_9029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laparoendoscopic single-site (single port) surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9029/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9029/contributors\">",
"     Pedro F Escobar, MD, FACS, FACOG",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9029/contributors\">",
"     Pedro T Ramirez, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9029/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9029/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9029/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9029/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/52/9029/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24328297\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoendoscopic single-site surgery (LESS), also referred to as single port laparoscopy, is one of the most recent advances in the field of minimally invasive surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/1\">",
"     1",
"    </a>",
"    ]. The technique utilizes a single skin incision, most commonly in the umbilicus, through which a port with multiple operating channels is introduced. Conventional laparoscopy is typically performed through two to four ports. Since the introduction of LESS, this approach has been applied to many surgical procedures.",
"   </p>",
"   <p>",
"    The role of LESS in laparoscopic surgery will be reviewed here. Related topics are discussed in detail separately, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General principles of laparoscopy (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=see_link\">",
"       \"Overview of conventional gynecologic laparoscopic surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=see_link\">",
"       \"Complications of gynecologic laparoscopic surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"       \"Abdominal access techniques used in laparoscopic surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Robot-assisted laparoscopy (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=see_link\">",
"       \"Robot-assisted laparoscopy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24328304\">",
"    <span class=\"h1\">",
"     HISTORY OF SINGLE-SITE LAPAROENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept of single-site surgery is not new in the field of gynecologic surgery. Laparoscopic sterilization has been performed through a single port by some surgeons. In one report in 1969, &ldquo;single trocar operative laparoscopy&rdquo; was performed using a 12 mm operative laparoscope with one operative channel [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In 1991, the first hysterectomy by a single trocar technique was reported by Pelosi, et al [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/4\">",
"     4",
"    </a>",
"    ]. Despite these pioneering efforts, gynecologic surgeons did not embrace single-site surgery until recently. The major reason for this has been a lack of instruments designed for single-site use, including a dedicated port system for single-site surgery, special articulating",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rotating instruments, and improved optical systems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24328311\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoendoscopic single-site surgery refers to all minimally invasive surgical procedures performed through a single incision. This term was introduced as standard terminology for academic publications in 2008 by the Laparoendoscopic Single-Site Surgery Consortium for Assessment and Research [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/1\">",
"     1",
"    </a>",
"    ]. These procedures are also referred to as single port laparoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24555461\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only specific contraindication for laparoendoscopic single-site surgery is previous mesh placement at the umbilicus. Otherwise, the indications and contraindications for laparoendoscopic single-site surgery are the same as for conventional and laparoscopic surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6844404\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoendoscopic single-site surgery (LESS) is performed through a single abdominal port, usually at the umbilicus. The port has multiple channels through which the laparoscope and operative instruments are passed (",
"    <a class=\"graphic graphic_figure graphicRef85541 \" href=\"UTD.htm?1/49/1808\">",
"     figure 1",
"    </a>",
"    ). LESS procedures usually involve two surgeons, the primary surgeon performing the procedure and the assistant manipulating the endoscope.",
"   </p>",
"   <p>",
"    The umbilicus may vary in terms of its depth, diameter, shape, and overall appearance. The surgeon typically makes a 1.5 to 2 cm umbilical incision. The surgeon&rsquo;s choice of transverse or vertical incision depends upon the anatomy of the umbilicus. Location and length of the incision for a single site approach compared with other approaches should be included in the informed consent discussion.",
"   </p>",
"   <p>",
"    Not all patients will be candidates for single-site surgery; as with any other minimally invasive surgery technique (laparoscopy or robotics), patient selection is a composite of clinical judgement, risk, benefits, alternatives and a well informed patient.",
"   </p>",
"   <p>",
"    For women undergoing hysterectomy, some surgeons use the vaginal cuff as an additional port through which to remove specimens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=see_link&amp;anchor=H24766314#H24766314\">",
"     \"Laparoscopic approach to hysterectomy\", section on 'Single port laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6844392\">",
"    <span class=\"h2\">",
"     Single-site versus conventional laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary advantage of LESS is that it is performed through a single port rather than the two to four ports required for conventional laparoscopy. This reduces surgical trauma and residual scarring, leaving the patient with a single incision, even for a major procedure such as hysterectomy.",
"   </p>",
"   <p>",
"    The use of a single port also results in the challenges inherent in LESS procedures. LESS utilizes a different geometry compared with other laparoscopic approaches. Conventional laparoscopy relies upon the basic concept of triangulating the surgical field, with the laparoscope at the apex and the operative instruments at the base [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/1\">",
"     1",
"    </a>",
"    ]. With the LESS approach, all instruments enter through a shared incision, thereby limiting the ability to triangulate the field. Close proximity of the instruments leads to significant clashing with one another. In addition, use of a single port results in challenges in terms of space and movement of the instruments by one or two surgeons outside the abdomen.",
"   </p>",
"   <p>",
"    The loss of triangulation results in the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clashing of instruments",
"     </li>",
"     <li>",
"      Reduced range of motion of the instruments",
"     </li>",
"     <li>",
"      Loss of depth perception",
"     </li>",
"     <li>",
"      Need for specialized training",
"     </li>",
"     <li>",
"      Poor surgeon ergonomics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advances in instrumentation, optics, and techniques have mitigated some of these limitations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115365\">",
"    <span class=\"h2\">",
"     Single-site robotic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Robotic assistance has been shown to be a useful tool when attempting single-port surgery. Initial data from animal and human procedures in urology appear promising [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Robotic single port device insertion is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef85541 \" href=\"UTD.htm?1/49/1808\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=see_link\">",
"     \"Robot-assisted laparoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical instruments have been developed to use either with the da Vinci&reg; robotic surgical system (VeSPA) or alone (ViKY&reg;) for LESS procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1117033\">",
"    <span class=\"h2\">",
"     Surgical training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specialized training is required to perform LESS procedures, and this type of training has not yet been incorporated uniformly in gynecologic residency programs. In evaluating the learning curve for LESS procedures, the authors of one study reported that the most significant improvement in operative time occurred after 10 completed cases and a smaller improvement after 20 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6844314\">",
"    <span class=\"h1\">",
"     INSTRUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of dedicated port systems and instrumentation are currently available for laparoendoscopic single-site surgery (LESS). Surgeons are encouraged to familiarize themselves with the available technology in order to select the best options for their surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24328318\">",
"    <span class=\"h2\">",
"     Abdominal port systems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single-site laparoendoscopic surgery requires a port with multiple channels (",
"    <a class=\"graphic graphic_figure graphicRef85541 \" href=\"UTD.htm?1/49/1808\">",
"     figure 1",
"    </a>",
"    ). There are currently many port systems available (eg, SILS",
"    <sup>",
"     TM",
"    </sup>",
"    ,",
"    <sup>",
"    </sup>",
"    GelPoint&reg;, QuadPort, Cuschieri Endocone&reg;).",
"   </p>",
"   <p>",
"    The port systems vary in the size of fascial incision they can accommodate, ranging from 1.2 to 7 cm. They also have differing numbers (three to four) and combinations of channel sizes (5 mm to 15 mm).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24328325\">",
"    <span class=\"h2\">",
"     Laparoscopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the challenges of LESS is that multiple operative instruments enter through the same port. The appropriate selection of a laparoscope is important to avoid clashing of the instruments outside or within the abdomen.",
"   </p>",
"   <p>",
"    Small diameter (5 to 10 mm), low-profile cameras with in-line light cords have been developed to reduce extracorporal bulk of conventional laparoscopes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/11\">",
"     11",
"    </a>",
"    ]. A long bariatric scope with an angled light cord and low-profile camera may be used.",
"   </p>",
"   <p>",
"    In addition, the optics must help the surgeon visualize the surgical field, while at the same time helping to avoid clashing of instruments. Camera features that help with this include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An angled camera lens that allows for visualization above or below the plane of other instruments.",
"     </li>",
"     <li>",
"      A flexible laparoscope that can provide a 100&deg; field of view from multiple angles (eg, LTF-VH, Ideal Eyes&reg;). This eliminates the need to change between 0&deg; and 30&deg; scopes intraoperatively. Some systems allow the surgeon to toggle between rigid and flexible tip camera images with the push of a button, adding efficiency during the surgery. &nbsp;",
"     </li>",
"     <li>",
"      A variable viewing laparoscope that allows adjustment of the viewing direction of the lens from 0 to 120&deg; rather than the shaft (eg, Endocameleon&reg;).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6844381\">",
"    <span class=\"h2\">",
"     Operative instruments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A primary challenge of the LESS approach is the potential for clashing of instruments and reduced range of motion, as noted above (see",
"    <a class=\"local\" href=\"#H6844392\">",
"     'Single-site versus conventional laparoscopy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"     \"Abdominal access techniques used in laparoscopic surgery\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Flexible and articulating instruments have been introduced to address the issues of crowding of instruments. These instruments enter the patient in the midline and in parallel, but then are able to approach the operative field laterally and from different angles. Use of these instruments also improves the ability to separate instruments outside the abdomen.",
"   </p>",
"   <p>",
"    While not all currently available instruments have flexible articulating capability, the essential instruments for minimally invasive surgery (eg, Maryland graspers and scissors) are available with these features (eg, Roticulator&trade;, RealHand, Spider&reg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/12\">",
"     12",
"    </a>",
"    ]. Flexible articulating energy devices are not yet available, but the use of rigid energy devices along with articulating graspers for retraction affords sufficient exposure to accomplish LESS procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24328332\">",
"    <span class=\"h1\">",
"     CLINICAL APPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoendoscopic single-site surgery (LESS) techniques are currently being developed in all abdominal surgery fields (gynecology, general surgery, urology) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9029/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. To date, the application of LESS in gynecology includes ovarian cystectomy, salpingo-oophorectomy, and hysterectomy, as well as several oncologic procedures. LESS is a new approach, and requires further study. Available data suggest that the LESS approach has similar operative outcomes as conventional laparoscopy and that LESS may be associated with less pain during the immediate postoperative period.",
"   </p>",
"   <p>",
"    Use of LESS for specific procedures is discussed in the topic reviews for those procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=see_link\">",
"     \"Laparoscopic approach to hysterectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=see_link&amp;anchor=H24766314#H24766314\">",
"     \"Laparoscopic approach to hysterectomy\", section on 'Single port laparoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link&amp;anchor=H10497613#H10497613\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Single port laparoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H17#H17\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Robot-assisted or single port laparoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24328388\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laparoendoscopic single-site surgery (LESS), also referred to as single port laparoscopy, is one of the most recent advances in the field of minimally invasive surgery. The technique utilizes a single skin incision, most commonly in the umbilicus, through which a port with multiple operating channels is introduced. (See",
"      <a class=\"local\" href=\"#H24328297\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"       \"Abdominal access techniques used in laparoscopic surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The primary advantage of LESS is that it is performed through a single port rather than the two to four ports required for conventional laparoscopy. This reduces surgical trauma and residual scarring, leaving the patient with a single incision. (See",
"      <a class=\"local\" href=\"#H6844404\">",
"       'Surgical technique'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"       \"Abdominal access techniques used in laparoscopic surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of a single incision also results in the loss of triangulation, which can lead to issues of crowding of instruments, loss of depth perception, and poor surgeon ergonomics. Advances in instrumentation, optics, and techniques have mitigated some of these limitations. (See",
"      <a class=\"local\" href=\"#H6844404\">",
"       'Surgical technique'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6844314\">",
"       'Instrumentation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"       \"Abdominal access techniques used in laparoscopic surgery\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Robotic devices have also been used in conjunction with LESS procedures. (See",
"      <a class=\"local\" href=\"#H1115365\">",
"       'Single-site robotic surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"       \"Abdominal access techniques used in laparoscopic surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/1\">",
"      Gill IS, Advincula AP, Aron M, et al. Consensus statement of the consortium for laparoendoscopic single-site surgery. Surg Endosc 2010; 24:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/2\">",
"      Pelosi MA, Pelosi MA 3rd. Laparoscopic hysterectomy with bilateral salpingo-oophorectomy using a single umbilical puncture. N J Med 1991; 88:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/3\">",
"      Wheeless CR. A rapid, inexpensive and effective method of surgical sterilization by laparoscopy. J Reprod Med 1969; 3:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/4\">",
"      Wheeless CR Jr, Thompson BH. Laparoscopic sterilization. Review of 3600 cases. Obstet Gynecol 1973; 42:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/5\">",
"      Haber GP, Crouzet S, Kamoi K, et al. Robotic NOTES (Natural Orifice Translumenal Endoscopic Surgery) in reconstructive urology: initial laboratory experience. Urology 2008; 71:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/6\">",
"      Kaouk JH, Goel RK, Haber GP, et al. Robotic single-port transumbilical surgery in humans: initial report. BJU Int 2009; 103:366.",
"     </a>",
"    </li>",
"    <li>",
"     Escobar PF, Pascal Haber G, Kaouk J, Kroh M, Chalikonda S, Falcone T. Single-Port Surgery: Laboratory Experience with the da Vinci &ldquo;VeSPA&rdquo; Platform. JSLS 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/8\">",
"      Haber GP, White MA, Autorino R, et al. Novel robotic da Vinci instruments for laparoendoscopic single-site surgery. Urology 2010; 76:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/9\">",
"      Hung AJ, Abreu AL, Shoji S, et al. Robotic transrectal ultrasonography during robot-assisted radical prostatectomy. Eur Urol 2012; 62:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/10\">",
"      Fader AN, Cohen S, Escobar PF, Gunderson C. Laparoendoscopic single-site surgery in gynecology. Curr Opin Obstet Gynecol 2010; 22:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/11\">",
"      Autorino R, Cadeddu JA, Desai MM, et al. Laparoendoscopic single-site and natural orifice transluminal endoscopic surgery in urology: a critical analysis of the literature. Eur Urol 2011; 59:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/12\">",
"      Pryor AD, Tushar JR, DiBernardo LR. Single-port cholecystectomy with the TransEnterix SPIDER: simple and safe. Surg Endosc 2010; 24:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/13\">",
"      Stolzenburg JU, Kallidonis P, Till H, et al. Current status of laparoendoscopic single-site surgery in urology. World J Urol 2009; 27:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9029/abstract/14\">",
"      Froghi F, Sodergren MH, Darzi A, Paraskeva P. Single-incision Laparoscopic Surgery (SILS) in general surgery: a review of current practice. Surg Laparosc Endosc Percutan Tech 2010; 20:191.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14188 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-BE0BA8F269-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9029=[""].join("\n");
var outline_f8_52_9029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24328388\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24328297\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24328304\">",
"      HISTORY OF SINGLE-SITE LAPAROENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24328311\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24555461\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6844404\">",
"      SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6844392\">",
"      Single-site versus conventional laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1115365\">",
"      Single-site robotic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1117033\">",
"      Surgical training",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6844314\">",
"      INSTRUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24328318\">",
"      Abdominal port systems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24328325\">",
"      Laparoscopes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6844381\">",
"      Operative instruments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24328332\">",
"      CLINICAL APPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24328388\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14188|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/49/1808\" title=\"figure 1\">",
"      Single port laparosc set-up",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/15/7415?source=related_link\">",
"      Complications of gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=related_link\">",
"      Laparoscopic approach to hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=related_link\">",
"      Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17334?source=related_link\">",
"      Overview of conventional gynecologic laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/34/27176?source=related_link\">",
"      Robot-assisted laparoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_52_9030="Treatment of sleep-disordered breathing in COPD";
var content_f8_52_9030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"24\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of sleep-disordered breathing in COPD",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9030/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9030/contributors\">",
"     Peter C Gay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9030/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9030/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9030/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9030/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9030/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/52/9030/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in nocturnal gas exchange, particularly oxygen desaturation, are an important clinical problem in patients with chronic obstructive pulmonary disease (COPD) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. The general management of sleep-disordered breathing in COPD, including the role positive airway pressure, oxygen therapy, pharmacologic agents, and lung volume reduction surgery, will be reviewed here. The diagnostic approach to patients with COPD and suspected sleep disordered breathing, and the use of nocturnal ventilatory support in patients with COPD, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22150?source=see_link\">",
"     \"Sleep-disordered breathing in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19063?source=see_link\">",
"     \"Nocturnal ventilatory support in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POSITIVE AIRWAY PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians need to be aware of the \"overlap syndrome\" which describes patients with both obstructive sleep apnea (OSA, a disorder characterized by obstructive apneas and hypopneas) and chronic obstructive pulmonary disease (COPD), resulting in gas exchange abnormalities, sleep disturbances, and symptoms seemingly out of proportion to the degree of airway obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/6\">",
"     6",
"    </a>",
"    ]. Patients with COPD who are hypercapnic with only moderate obstruction should be questioned regarding symptoms OSA, especially if they are obese snorers and report headache after nocturnal oxygen therapy. Although continuous positive airway pressure (CPAP) treatment has never been shown to be of benefit in patients with COPD alone, the component of OSA that exists in patients with the overlap syndrome will respond to CPAP therapy.",
"   </p>",
"   <p>",
"    In the 'Sleep Heart Health Study', comparison of patients with mild COPD versus patients without COPD demonstrated a similar prevalence of OSA (22 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/7\">",
"     7",
"    </a>",
"    ]. However, the patients with both COPD and OSA had more desaturation and sleep disruption than patients with COPD alone.",
"   </p>",
"   <p>",
"    Obesity hypoventilation syndrome (OHS) may also occur in COPD patients. OHS should be considered if there is hypercapnia out of proportion to the severity of the air flow obstruction. Further evaluation is indicated when OHS is suspected since OHS may require nocturnal ventilatory support.",
"   </p>",
"   <p>",
"    In a review of 219 consecutive patients with OSA, the prevalence of hypercapnia (defined as PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;45 mmHg) was 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/8\">",
"     8",
"    </a>",
"    ]. Most of the patients with hypercapnia had OSA alone (77 percent), although patients with coexisting COPD (10 percent) or OHS (13 percent) were also identified. Patients with OHS plus COPD had more severe hypercapnia and nocturnal desaturations than patients with the overlap syndrome or OSA alone.",
"   </p>",
"   <p>",
"    Patients with OSA plus chronic bronchitis, OHS, or COPD are more likely to develop cor pulmonale or heart failure and have a poorer prognosis than patients with OSA alone; increased mortality is associated with an increase of PaCO",
"    <sub>",
"     2",
"    </sub>",
"    during the first 6 to 18 months of long-term oxygen therapy&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. We believe that an arterial blood gas should be obtained from patients with OSA if there is a suspicion of hypercapnia as this may have prognostic significance and may also identify the need to treat coexisting forms of nocturnal hypoventilation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OXYGEN THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term oxygen administration is the mainstay of therapy for hypoxemic patients with COPD. Correction of hypoxemia for at least 15 hours per day has been shown to increase survival, reduce pulmonary hypertension, and improve neurologic function (",
"    <a class=\"graphic graphic_figure graphicRef82598 \" href=\"UTD.htm?38/49/39709\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data are available regarding the benefit of treating isolated nocturnal hypoxemia with supplemental oxygen. One study evaluated the benefit of nocturnal supplemental oxygen in COPD patients with daytime PaO",
"    <sub>",
"     2",
"    </sub>",
"    above 60 mmHg, but with oxygen desaturation to 85 percent or less for at least 5 minutes during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients were assigned to treatment with nasal supplemental oxygen or air (sham) in a double-blind fashion for three years and were then followed for an additional three years unless removed from the study due to clinical need for daytime oxygen, dropout, or death. The study is revealed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Random eye movement (REM) sleep desaturation was associated with increased mortality.",
"     </li>",
"     <li>",
"      There was no difference in mortality when patients receiving oxygen were compared to patients receiving sham.",
"     </li>",
"     <li>",
"      Oxygen therapy was associated with a small but significant fall in pulmonary artery pressure (-3.7 mmHg) compared to sham (+3.9 mmHg).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate study found that oxygen did not improve sleep quality in patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A controlled trial evaluated the impact of oxygen therapy on the hemodynamics and survival of 135 patients with daytime PaO",
"    <sub>",
"     2",
"    </sub>",
"    = 56 to 69 mmHg and nocturnal oxygen desaturation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients were randomly assigned to receive nocturnal oxygen therapy (to maintain SpO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;90 percent) or sham, then evaluated every three months for three years or until death. Nocturnal oxygen did not delay the prescription of long-term oxygen therapy and had no effect on survival. Sleep quality was not assessed during the study.",
"   </p>",
"   <p>",
"    Despite the paucity of data, it has generally been recommended that patients who demonstrate sustained oxygen desaturation at night to 88 percent or less be treated with nocturnal supplemental oxygen. The clinician should be alert to the presence of awake hypercapnia in patients who are being considered for supplemental oxygen therapy, since there is evidence suggesting that oxygen may cause worsening of sleep disordered breathing in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/17\">",
"     17",
"    </a>",
"    ]. However, another study found only a minor effect [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/18\">",
"     18",
"    </a>",
"    ]. Supplemental oxygen given at night to patients with severe COPD (mean arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    53 mmHg) was associated with only small (less than 6 mmHg) increases in arterial PCO",
"    <sub>",
"     2",
"    </sub>",
"    throughout sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=see_link\">",
"     \"Use of oxygen in patients with hypercapnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Methods for delivering oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nocturnal oxygen therapy can be provided from a concentrator or from liquid or gaseous delivery systems. A concentrator is the least expensive approach for nocturnal use. The oxygen can be delivered either by a nasal cannula or a transtracheal catheter. Although placement of a transtracheal catheter requires a mini-surgical procedure and more maintenance, it is less likely to become dislodged during sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/19\">",
"     19",
"    </a>",
"    ]. For a variety of reasons, oxygen delivered by a home concentrator and nasal cannula is preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21927?source=see_link\">",
"     \"Oxygen conserving devices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37015?source=see_link\">",
"     \"Transtracheal oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Oxygen prescription",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amount of oxygen prescribed should ideally be determined with overnight pulse oximetry. Daytime estimates of nocturnal oxygen requirements appear to be inaccurate in a large number of patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/20\">",
"     20",
"    </a>",
"    ]. In the United States, the Centers for Medicare and Medicaid updated the reimbursement criteria for home oxygen therapy in 2004. These criteria vary from region to region, and play a major role in determining the availability of nocturnal oxygen for patients covered by Medicare [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Updated guidelines from the American Thoracic Society and the European Respiratory Society on home oxygen therapy for patients with COPD are expected in 2006. In addition, the results of the 6th Oxygen Consensus Conference and new Medicare coverage criteria for oxygen therapy in COPD patients are expected to be published later in 2006 and will include issues regarding sleep. The NIH has recently launched an effort to stimulate studies to guide the selection of COPD patients with less severe daytime hypoxemia who will benefit from long term oxygen therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacotherapy has not made a great impact on the problem of sleep-disordered breathing in COPD. The majority of these agents effect ventilatory control mechanisms and act as respiratory stimulants; however, the effects are usually modest",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    not sustained. Other agents are targeted toward decreasing airway or pulmonary vascular resistance or improving respiratory muscle efficiency. The most widely studied drugs include progestational agents, in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"     protriptyline",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Respiratory stimulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hyperventilatory effect of pregnancy has long been recognized to be directly attributable to high levels of circulating progesterone. As a result, progesterone has been studied as a respiratory stimulant primarily in patients with obesity hypoventilation syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39446?source=see_link\">",
"     \"Dyspnea during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=see_link\">",
"     \"Treatment of the obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several reports have now examined the use of progesterone in patients with COPD. Studies in the 1980s indicated that those hypercapnic patients with COPD (many of whom were obese) who were able to voluntarily hyperventilate and reduce PaCO",
"    <sub>",
"     2",
"    </sub>",
"    and who increased their tidal volume in response to medroxyprogesterone therapy were able to significantly reduce daytime PaCO",
"    <sub>",
"     2",
"    </sub>",
"    after four weeks of progesterone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent randomized crossover study examined the effect of both systemic progesterone and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    on awake and asleep gas exchange in hypoxemic patients with COPD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/23\">",
"     23",
"    </a>",
"    ]. Favorable, but small (3 to 5 mmHg), effects were seen on awake and asleep PaCO",
"    <sub>",
"     2",
"    </sub>",
"    with both drugs, but only acetazolamide improved awake and asleep oxygenation. The effects of long-term acetazolamide have not been examined. In addition, most patients do not appreciate the water retention associated with the use of progesterone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in sleep-disordered breathing associated with COPD is based upon the following mechanisms of action:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A reduction of nocturnal airway obstruction",
"     </li>",
"     <li>",
"      A direct stimulatory effect on respiratory control mechanisms",
"     </li>",
"     <li>",
"      An effect on respiratory muscle contractile mechanisms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several studies have evaluated the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    in patients with COPD and sleep disordered breathing with differing results. At best, sleep was unaltered by theophylline use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In addition, improvement of spirometry was not associated with improvement of sleep quality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All the above studies suffer from a potential confounding influence of the \"single night effect,\" ie, the possibility that the study night is influenced by the lab conditions and is not representative of the patient's typical sleep. In addition, variations in the relatively small patient populations make it difficult to compare the trials directly. Overall, it is doubtful that sustained release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    at bedtime, even in patients who appear to tolerate the drug, will benefit sleep quality. We believe that clinicians should base the continuation of theophylline therapy on its own merits, but might inquire about any subjective effects on sleep quality noted by the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Protriptyline",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"     Protriptyline",
"    </a>",
"    is a non-sedating tricyclic antidepressant that alters sleep architecture by reducing the amount of rapid eye movement (REM) sleep. It may theoretically be useful in the setting of sleep-disordered breathing in COPD, because such patients are most likely to hypoventilate and experience significant degrees of oxygen desaturation during REM sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22150?source=see_link\">",
"     \"Sleep-disordered breathing in COPD\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study found that patients with stable COPD showed no change in sleep efficiency or sleep latency after two to four months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"     protriptyline",
"    </a>",
"    therapy, but REM sleep was reduced by 8 to 16 percent. Nocturnal oxygen saturation was improved, although the extent of improvement was not clear. However, 20 percent of patients could not tolerate the drug, and the majority complained of dry mouth and urinary problems [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/28\">",
"     28",
"    </a>",
"    ]. As a result, the drug is rarely used in men unless all other options have failed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     LUNG VOLUME REDUCTION SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using a small subgroup of patients who participated in the National Emphysema Treatment Trial (NETT), the effect of lung volume reduction surgery (LVRS) on sleep quality and nocturnal gas exchange was investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9030/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Polysomnography and spirometry was performed on 16 patients before and after receiving either medical therapy alone (6 pts) or medical therapy plus LVRS (10 pts). LVRS was associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improved total sleep time and sleep efficiency",
"     </li>",
"     <li>",
"      Improved mean and lowest nocturnal oxygen saturation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These values directly correlated with the increase in FEV1 and inversely correlated with the change in residual volume or functional residual capacity with improvement in the lowest nocturnal oxygen saturation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oxygen is the mainstay of therapy for virtually all COPD patients with nocturnal desaturation after optimizing COPD therapy. In those patients with nocturnal cough, dyspnea, or wheeze, more aggressive bronchodilator or anti-inflammatory agents can be added after excluding or empirically treating other causes such as heart failure or reflux. In those patients already using nocturnal oxygen therapy who have a change in their clinical status or significant desaturation with exercise, screening overnight oximetry and an arterial blood gas may be performed after a careful history to assess for overlooked obstructive apnea. In those patients who demonstrate abnormal oximetry with supplemental oxygen, hypercapnia, or symptoms of sleep disordered breathing, polysomnography may be warranted, with further treatment as indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22150?source=see_link\">",
"     \"Sleep-disordered breathing in COPD\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/1\">",
"      Weitzenblum E, Chaouat A. Sleep and chronic obstructive pulmonary disease. Sleep Med Rev 2004; 8:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/2\">",
"      Gay PC. Chronic obstructive pulmonary disease and sleep. Respir Care 2004; 49:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/3\">",
"      McNicholas WT. Impact of sleep in COPD. Chest 2000; 117:48S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/4\">",
"      Kutty K. Sleep and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2004; 10:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/5\">",
"      Fanfulla F, Cascone L, Taurino AE. Sleep disordered breathing in patients with chronic obstructive pulmonary disease. Minerva Med 2004; 95:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/6\">",
"      Flenley DC. Sleep in chronic obstructive lung disease. Clin Chest Med 1985; 6:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/7\">",
"      Sanders MH, Newman AB, Haggerty CL, et al. Sleep and sleep-disordered breathing in adults with predominantly mild obstructive airway disease. Am J Respir Crit Care Med 2003; 167:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/8\">",
"      Resta O, Foschino Barbaro MP, Bonfitto P, et al. Hypercapnia in obstructive sleep apnoea syndrome. Neth J Med 2000; 56:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/9\">",
"      Weitzenblum E, Krieger J, Oswald M, et al. Chronic obstructive pulmonary disease and sleep apnea syndrome. Sleep 1992; 15:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/10\">",
"      Bradley TD. Right and left ventricular functional impairment and sleep apnea. Clin Chest Med 1992; 13:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/11\">",
"      Aida A, Miyamoto K, Nishimura M, et al. Prognostic value of hypercapnia in patients with chronic respiratory failure during long-term oxygen therapy. Am J Respir Crit Care Med 1998; 158:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/12\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/13\">",
"      Fletcher EC, Levin DC. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. Chest 1984; 85:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/14\">",
"      Fletcher EC, Luckett RA, Goodnight-White S, et al. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime PaO2 above 60 mm Hg. Am Rev Respir Dis 1992; 145:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/15\">",
"      Fleetham J, West P, Mezon B, et al. Sleep, arousals, and oxygen desaturation in chronic obstructive pulmonary disease. The effect of oxygen therapy. Am Rev Respir Dis 1982; 126:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/16\">",
"      G&oacute;recka D, Gorzelak K, Sliwi��ski P, et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/17\">",
"      Dunn WF, Nelson SB, Hubmayr RD. Oxygen-induced hypercarbia in obstructive pulmonary disease. Am Rev Respir Dis 1991; 144:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/18\">",
"      Goldstein RS, Ramcharan V, Bowes G, et al. Effect of supplemental nocturnal oxygen on gas exchange in patients with severe obstructive lung disease. N Engl J Med 1984; 310:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/19\">",
"      Hoffman LA, Wesmiller SW, Sciurba FC, et al. Nasal cannula and transtracheal oxygen delivery. A comparison of patient response after 6 months of each technique. Am Rev Respir Dis 1992; 145:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/20\">",
"      Sliwi��ski P, Lagosz M, G&oacute;recka D, Zieli��ski J. The adequacy of oxygenation in COPD patients undergoing long-term oxygen therapy assessed by pulse oximetry at home. Eur Respir J 1994; 7:274.",
"     </a>",
"    </li>",
"    <li>",
"     Oxygen and Oxygen Equipment. www.palmettogba.com/palmetto/lmrps_dmerc.nsf/final/7CEAE45C2D87DB7F85256E4D00646133?OpenDocument (Accessed on April 25, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/22\">",
"      Skatrud JB, Dempsey JA, Bhansali P, Irvin C. Determinants of chronic carbon dioxide retention and its correction in humans. J Clin Invest 1980; 65:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/23\">",
"      Vos PJ, Folgering HT, de Boo TM, et al. Effects of chlormadinone acetate, acetazolamide and oxygen on awake and asleep gas exchange in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1994; 7:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/24\">",
"      Berry RB, Desa MM, Branum JP, Light RW. Effect of theophylline on sleep and sleep-disordered breathing in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 143:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/25\">",
"      Brander PE, Salmi T. Nocturnal oxygen saturation and sleep quality in patients with advanced chronic obstructive pulmonary disease during treatment with moderate dose CR-theophylline. Eur J Clin Pharmacol 1992; 43:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/26\">",
"      Martin RJ, Pak J. Overnight theophylline concentrations and effects on sleep and lung function in chronic obstructive pulmonary disease. Am Rev Respir Dis 1992; 145:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/27\">",
"      Mulloy E, McNicholas WT. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1993; 148:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/28\">",
"      Lin CC. [Effects of protriptyline on day and night time oxygenation in patients with chronic obstructive pulmonary disease]. J Formos Med Assoc 1993; 92 Suppl 4:S232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/29\">",
"      Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003; 348:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9030/abstract/30\">",
"      Krachman SL, Chatila W, Martin UJ, et al. Effects of lung volume reduction surgery on sleep quality and nocturnal gas exchange in patients with severe emphysema. Chest 2005; 128:3221.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1432 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9030=[""].join("\n");
var outline_f8_52_9030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POSITIVE AIRWAY PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OXYGEN THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Methods for delivering oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Oxygen prescription",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Respiratory stimulants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Protriptyline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      LUNG VOLUME REDUCTION SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1432|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/49/39709\" title=\"figure 1\">",
"      Benefit of LTOT in NOTT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/33/39446?source=related_link\">",
"      Dyspnea during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19063?source=related_link\">",
"      Nocturnal ventilatory support in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21927?source=related_link\">",
"      Oxygen conserving devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22150?source=related_link\">",
"      Sleep-disordered breathing in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37015?source=related_link\">",
"      Transtracheal oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29192?source=related_link\">",
"      Treatment of the obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3064?source=related_link\">",
"      Use of oxygen in patients with hypercapnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_52_9031="Progestin-only pills (minipills) for contraception";
var content_f8_52_9031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Progestin-only pills (minipills) for contraception",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9031/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9031/contributors\">",
"     Andrew M Kaunitz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9031/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9031/contributors\">",
"     Mimi Zieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9031/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9031/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/52/9031/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin-only contraception is an option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns. Only one progestin-only oral contraceptive (OC) formulation is marketed in the United States:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    0.35 mg tablets (Micronor, Nor-QD, and generics). The progestin dose is substantially lower than the dose in any combination oral contraceptive. It is dispensed in packs of 28 active pills, which are taken continuously (ie, no pill free or nonhormonal pill week) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other types of progestin-only contraceptives include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progestin injections (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link\">",
"       \"Depot medroxyprogesterone acetate for contraception\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Progestin implants (eg, Implanon, Jadelle) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=see_link\">",
"       \"Etonogestrel contraceptive implant\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intrauterine contraception (eg, Mirena) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=see_link\">",
"       \"Overview of intrauterine contraception\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It should be noted that in some areas of the world, desogestrel is available as a 75 mcg progestin-only OC formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/2\">",
"     2",
"    </a>",
"    ]. This formulation has significant differences from the progestin-only OCs discussed in this topic: the main mechanism of action is inhibition of ovulation, contraceptive efficacy is as high as estrogen-progestin OCs, and intake delay of up to 12 hours does not affect its contraceptive efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin-only OCs work by suppressing ovulation, thickening cervical mucus, and thinning the endometrium. In contrast to oral estrogen-progestin contraceptive pills (OCs), ovulation is not consistently suppressed. Therefore, the effects of progestin-only OCs on cervical mucus and endometrium are the critical factors in prevention of conception [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/3\">",
"     3",
"    </a>",
"    ]. Within hours of administration, progestin-only OCs reduce the volume of cervical mucus and increase its viscosity, which prevents sperm from passing through the cervical canal and endometrial cavity. These changes persist for only 20 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;National survey data used to estimate contraceptive failure rates with typical use have not distinguished between users of combination OCs (8 percent failure rate in first year of use) and progestin-only OCs. Because the great majority of OCs used in the United States represent combination OCs, and the failure rate with progestin-only OCs is likely to be higher than with combination OCs, the typical failure rate with progestin-only OCs is likely to be higher than 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the US, many women who use progestin-only OCs are subfertile as a result of breast feeding or older reproductive age. Thus, the failure rate of progestin-only OC in these populations is lower than in more fertile populations [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Some clinicians have speculated that taking daily dose of two or more progestin-only OC tablets (two tablets as a single dose) might increase the contraceptive efficacy of progestin-only OCs in young, nonlactating women who are presumably highly fecund [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. However, there are no published data regarding this off-label contraceptive strategy. There are also no data regarding contraceptive efficacy in obese fertile women.",
"   </p>",
"   <p>",
"    An oral formulation combining 5 mcg of ethinyl estradiol and 1 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone acetate",
"    </a>",
"    (femHRT",
"    <span class=\"nowrap\">",
"     1/5)",
"    </span>",
"    is marketed for the treatment of menopausal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/10\">",
"     10",
"    </a>",
"    ]. Because this dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    acetate appears sufficient to consistently suppress ovulation and the dose of estrogen is small, some clinicians prescribe this combination medication off-label to women requiring contraception who medically are not candidates for conventional combination estrogen-progestin contraceptives. Such women should be counseled that femHRT",
"    <span class=\"nowrap\">",
"     1/5",
"    </span>",
"    is not approved for contraceptive use and that condom back-up is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that minipills be initiated on the first day of menses, and a back-up contraceptive be used for the first week. Because of the short duration of action and the short half-life of progestin-only OCs, it is",
"    <strong>",
"     essential",
"    </strong>",
"    that the pill be taken at the same time each day to maximize contraceptive efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A back-up contraceptive (eg, condoms) should be used for at least two days if the progestin-only OC is taken more than three hours late or forgotten on any given day. The patient should also resume taking daily progestin-only OCs as soon as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some clinicians initiate progestin-only OCs at any time in the cycle, as long as the clinician is reasonably certain that the patient is not pregnant. Back-up contraception should be used for the first seven days of use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Menstrual changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with all continuous progestin-only contraceptives, menstrual irregularities are common in progestin-only OC users and represent the most frequent cause for contraceptive discontinuation. Unscheduled bleeding, spotting, and amenorrhea are common menstrual patterns during progestin-only OC use, and prospective, as well as current, users should be counseled accordingly. However, prolonged episodes of bleeding or amenorrhea occur less frequently than in depot-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (DMPA) users [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interpreting signs and symptoms of pregnancy, whether intrauterine or extrauterine, can be challenging in progestin-only OC users. Pregnancy testing is appropriate for progestin-only OC users experiencing nausea, breast tenderness, a change in menstrual pattern or lower abdominal pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Follicular cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonographic studies have shown that follicular cysts are more common in progestin-only OC users than other women [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/15\">",
"     15",
"    </a>",
"    ]. The follicular changes tend to increase and regress over time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. No intervention is required in asymptomatic women, other than reassurance and sonographic follow-up. If a follow-up sonogram in six to eight weeks demonstrates resolution or decrease in size of follicular cysts, no further evaluation is required. Progestin-only OC users who have persistent concerns about ovarian follicular changes should be offered another method of contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acne",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acne may flare, likely reflecting the androgenic nature of the progestin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight gain is not a side effect of progestin-only OCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Headache",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin-only OCs are less likely to cause headaches than other hormonal contraceptives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RISKS AND BENEFITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin-only contraception is an option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although clinicians should familiarize themselves with the contraindications listed on package labeling for all medications they prescribe, progestin-only hormonal methods appear to be appropriate contraceptive choices for many women with contraindications to estrogen-containing contraceptives. Many of the contraindications listed in the package insert were established for combined estrogen-progestin OCs and then extrapolated to progestin-only methods because clinical trials have not evaluated the safety of the latter in women with contraindications to estrogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link\">",
"     \"Risks and side effects associated with estrogen-progestin contraceptives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Given the low dose of hormone, the failure rate of progestin-only OCs in highly fertile women is higher than that with other hormonal contraceptive methods. However, serious complications are less common than with combined estrogen-progestin contraceptives [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/18\">",
"     18",
"    </a>",
"    ], and the method is less invasive and more readily reversible than progestin injections, implants, and intrauterine contraception.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Effect on cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin-only OCs have little effect on coagulation factors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/19\">",
"     19",
"    </a>",
"    ], blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], or lipid levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/19,20,22,23\">",
"     19,20,22,23",
"    </a>",
"    ]. Large epidemiologic studies have not identified a statistically increased risk of stroke, myocardial infarction, or venous thromboembolism with use of progestin-only OCs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. Thus, we and others [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/28\">",
"     28",
"    </a>",
"    ] believe progestin-only OCs represent a reasonable contraceptive choice for women at high risk of, or known, coronary artery disease, cerebrovascular disease, venous thromboembolic disease, hypertension, or other conditions in which use of contraceptive doses of estrogen are contraindicated. This recommendation differs from package labeling for some progestin-only contraceptives, which indicates that a prior history of thrombosis is a contraindication to use (eg, package labeling for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"     norethindrone",
"    </a>",
"    minipills was liberalized; labeling for DMPA has not been liberalized).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Effect of carbohydrate metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have reported that progestin-only OCs have little impact on carbohydrate metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/19,20,22,23\">",
"     19,20,22,23",
"    </a>",
"    ]. However, one study conducted in Latina women observed that lactating women with a history of gestational diabetes who used progestin-only OCs postpartum had an elevated risk of being diagnosed with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/29\">",
"     29",
"    </a>",
"    ]. After adjustment for potential confounding factors, the use of minipills almost tripled the risk of type 2 diabetes mellitus compared with equivalent use of low-dose combination OCs (adjusted relative risk, 2.87; 95% CI 1.57-5.27). Based on this one study, we suggest clinicians monitor glucose tolerance in high risk lactating women using progestin-only OCs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ectopic pregnancy risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin-only OCs lower the overall risk of ectopic pregnancy, as well as intrauterine pregnancy, by preventing ovulation or conception. Since women taking progestin-only OCs do not appear to have a higher absolute risk of ectopic pregnancy than women using no contraception, a history of ectopic pregnancy does not contraindicate progestin-only OC use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/1\">",
"     1",
"    </a>",
"    ]. However, if pregnancy occurs, the likelihood that the pregnancy is ectopic is higher in progestin-only OC users than in noncontraceptors (5 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Effect on bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only study assessing skeletal health in progestin-only OC users was conducted in breast feeding women. Although breast feeding resulted in a reversible reduction in spinal bone mineral density in women using barrier contraception, the small amounts of hormone in the progestin-only OC protected against this loss [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Older reproductive age women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduced fecundity of women over age 35 to 40 years means they can expect high contraceptive efficacy with use of progestin-only OCs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/3\">",
"     3",
"    </a>",
"    ]. As discussed above, younger highly fecund women wishing to achieve high contraceptive efficacy with progestin-only OCs may take two tablets (off-label) daily [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Effect on cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daily use of a progestin protects against development of endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/32\">",
"     32",
"    </a>",
"    ]. There is little epidemiologic data on the effect of progestin-only OCs on cancer risk. Available data suggest that associations between minipill use and reproductive cancers parallel known associations with combination OCs, in particular breast cancer risk does not appear to be significantly different from that in nonusers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Effect on sexually transmitted infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of progestin-only OCs does not protect users from acquiring sexually transmitted infections. However, thickened cervical mucous may reduce the risk of ascending infection with development of pelvic inflammatory disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     USE AFTER ABORTION OR DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progestin-only OCs may be initiated immediately postabortion or post delivery, and should be initiated by three weeks after delivery to assure effectiveness (",
"    <a class=\"graphic graphic_table graphicRef82680 \" href=\"UTD.htm?20/51/21311\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Breastfeeding women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The progestin-only OC does not interfere with the quality or quantity of breast milk [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/18,34\">",
"     18,34",
"    </a>",
"    ]. Very little progestin is passed from nursing mothers into their breast milk, and no adverse impact on infant growth has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9031/abstract/14\">",
"     14",
"    </a>",
"    ]. However, because the manufacturers of progestin-only OCs have not submitted data to the FDA regarding immediate postpartum use in lactating women, the package labeling advises delaying administration in lactating women until six weeks postpartum.",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists (ACOG) has stated that in certain clinical situations, such as concern about patient follow-up, it may be appropriate to start progesterone-containing contraception earlier. We concur, as our clinical experience at the University of Florida College of Medicine, Jacksonville, with immediate postpartum initiation of progestin-only contraceptives in lactating women is extensive and reassuring with respect to infant and maternal outcomes.",
"   </p>",
"   <p>",
"    WHO and CDC guidelines for use of hormonal contraception in breastfeeding women differ and are shown in the tables (",
"    <a class=\"graphic graphic_table graphicRef82680 \" href=\"UTD.htm?20/51/21311\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 2",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"       \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progestin-only contraception is an option for women in whom an estrogen-containing contraceptive is either contraindicated or causes additional health concerns. One progestin-only oral contraceptive (OC) formulation is marketed in the United States:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/52/16199?source=see_link\">",
"       norethindrone",
"      </a>",
"      0.35 mg tablets (Micronor, Nor-QD, and generics). The progestin dose is substantially lower than the dose in any combination oral contraceptive. The pills are dispensed in packs of 28 active pills, which are taken continuously (ie, no pill free or nonhormonal pill week). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ovulation is not consistently suppressed; the effects of progestin-only OCs on cervical mucus and endometrium are the critical factors in prevention of conception. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical user failure rate with progestin-only OCs is estimated to be over 8 percent. Women choosing progestin-only OCs are often subfertile as a result of breast feeding or older reproductive age so the failure rate in these populations is thought to be lower than in more fertile populations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is essential that the pill be taken at the same time each day to maximize contraceptive efficacy. A back-up contraceptive (eg, condoms) should be used for at least two days if the progestin-only OC is taken more than three hours late or forgotten on any given day. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Menstrual irregularities are common in progestin-only OC users and represent the most frequent cause for contraceptive discontinuation. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast to package labeling, we believe progestin-only OCs are an acceptable contraceptive option in women at increased risk of thrombosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Effect on cardiovascular risk'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Kaunitz, AM. Revisiting progestin-only OCs. Contemp OB/GYN 1997; 91.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/2\">",
"      Benagiano G, Primiero FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci 2003; 997:163.",
"     </a>",
"    </li>",
"    <li>",
"     Speroff, L, Darney, P. A Clinical Guide for Contraception, 4th ed, Baltimore, Williams and Wilkins, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/4\">",
"      Lebech PE, Svendsen PA, Ostergaard E, Koch F. The effects of small doses of megestrol acetate on the cervical mucus. Acta Obstet Gynecol Scand 1969; 48:Suppl 3:22+.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/5\">",
"      Wright SW, Fotherby K, Fairweather F. Effect of daily small doses of Norgestrel on ovarian function. J Obstet Gynaecol Br Commonw 1970; 77:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/6\">",
"      Trussell J. Contraceptive failure in the United States. Contraception 2004; 70:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/7\">",
"      Vessey, MP, Lawless, M, Yeates, D, et al. Progestogen-only oral contraception. Findings in a large prospective study with special reference to effectiveness. Br J Fam Plann 1985; 10:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/8\">",
"      Dunson TR, McLaurin VL, Grubb GS, Rosman AW. A multicenter clinical trial of a progestin-only oral contraceptive in lactating women. Contraception 1993; 47:23.",
"     </a>",
"    </li>",
"    <li>",
"     Guillebaud, J. Contraception: Your Questions Answered, 2nd ed, Churchill Livingstone, New York 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/10\">",
"      Simon JA, Wysocki S, Brandman J, Axelsen K. A comparison of therapy continuation rates of different hormone replacement agents: a 9-month retrospective, longitudinal analysis of pharmacy claims among new users. Menopause 2003; 10:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/11\">",
"      Brenner PF, Mishell DR Jr, Stanczyk FZ, Goebelsmann U. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel. Am J Obstet Gynecol 1977; 129:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/12\">",
"      Stanczyk FZ, Brenner PF, Mishell DR Jr, et al. A radioimmunoassay for norethindrone (NET): measurement of serum NET concentrations following ingestion of NET-containing oral contraceptive steroids. Contraception 1978; 18:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/13\">",
"      Weiner E, Victor A, Johansson ED. Plasma levels of d-norgestrel after oral administration. Contraception 1976; 14:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/14\">",
"      McCann MF, Potter LS. Progestin-only oral contraception: a comprehensive review. Contraception 1994; 50:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/15\">",
"      Tayob Y, Adams J, Jacobs HS, Guillebaud J. Ultrasound demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985; 92:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/16\">",
"      Shoupe D, Horenstein J, Mishell DR Jr, et al. Characteristics of ovarian follicular development in Norplant users. Fertil Steril 1991; 55:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/17\">",
"      Barbosa I, Bakos O, Olsson SE, et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42:51.",
"     </a>",
"    </li>",
"    <li>",
"     Maximizing the use of the progestin minipill. Contraceptive Technol Update 199; 20:19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/19\">",
"      Fotherby, K. The progestogen-only pill and thrombosis. Br J Fam Plann 1989; 15:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/20\">",
"      Ball MJ, Ashwell E, Gillmer MD. Progestagen-only oral contraceptives: comparison of the metabolic effects of levonorgestrel and norethisterone. Contraception 1991; 44:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/21\">",
"      Hussain SF. Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception 2004; 69:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/22\">",
"      Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/23\">",
"      Winkler UH. Blood coagulation and oral contraceptives. A critical review. Contraception 1998; 57:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/24\">",
"      Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 57:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/25\">",
"      Heinemann LA, Assmann A, DoMinh T, Garbe E. Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care 1999; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/26\">",
"      Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004; 164:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/27\">",
"      Lidegaard &Oslash;, L&oslash;kkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/28\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/29\">",
"      Kjos SL, Peters RK, Xiang A, et al. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus. JAMA 1998; 280:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/30\">",
"      Furlong LA. Ectopic pregnancy risk when contraception fails. A review. J Reprod Med 2002; 47:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/31\">",
"      Caird LE, Reid-Thomas V, Hannan WJ, et al. Oral progestogen-only contraception may protect against loss of bone mass in breast-feeding women. Clin Endocrinol (Oxf) 1994; 41:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/32\">",
"      Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/33\">",
"      Breast cancer and hormonal contraceptives: further results. Collaborative Group on Hormonal Factors in Breast Cancer. Contraception 1996; 54:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9031/abstract/34\">",
"      Halderman LD, Nelson AL. Impact of early postpartum administration of progestin-only hormonal contraceptives compared with nonhormonal contraceptives on short-term breast-feeding patterns. Am J Obstet Gynecol 2002; 186:1250.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5461 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9031=[""].join("\n");
var outline_f8_52_9031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Menstrual changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Follicular cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acne",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RISKS AND BENEFITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Effect on cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Effect of carbohydrate metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ectopic pregnancy risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Effect on bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Older reproductive age women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Effect on cancer risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Effect on sexually transmitted infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      USE AFTER ABORTION OR DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5461\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5461|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/51/21311\" title=\"table 1\">",
"      WHO MEC Personal characteristics and reproductive history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 2\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/27/3512?source=related_link\">",
"      Etonogestrel contraceptive implant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/19/32058?source=related_link\">",
"      Overview of intrauterine contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=related_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_52_9032="Echinostomiasis life cycle";
var content_f8_52_9032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63922&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Echinostomiasis life cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 493px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Many animals may serve as definitive hosts for various echinostome species, including aquatic birds, carnivores, rodents, and humans. Unembryonated eggs are passed in feces",
"    <strong>",
"     (1)",
"    </strong>",
"    and develop in the water",
"    <strong>",
"     (2)",
"    </strong>",
"    . The miracidium takes on average 10 days to mature before hatching",
"    <strong>",
"     (3)",
"    </strong>",
"    and penetrating the first intermediate host, a snail",
"    <strong>",
"     (4)",
"    </strong>",
"    . Several genera of snails may serve as the first intermediate host. The intramolluscan stages include a sporocyst",
"    <strong>",
"     (4a)",
"    </strong>",
"    , one or two generations of rediae",
"    <strong>",
"     (4b)",
"    </strong>",
"    , and cercariae",
"    <strong>",
"     (4c)",
"    </strong>",
"    . The cercariae may encyst as metacercariae within the same first intermediate host or leave the host and penetrate a new second intermediate host",
"    <strong>",
"     (5)",
"    </strong>",
"    . Depending on the species, several animals may serve as the second intermediate host, including other snails, bivalves, fish, and tadpoles. The definitive host becomes infected after eating infected second intermediate hosts",
"    <strong>",
"     (6)",
"    </strong>",
"    . Metacercariae excyst in the duodenum",
"    <strong>",
"     (7)",
"    </strong>",
"    , and adults reside in the small intestine",
"    <strong>",
"     (8)",
"    </strong>",
"    .",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Echinostomiasis. Available at:",
"     <a href=\"file://dpd.cdc.gov/dpdx/html/Echinostomiasis.htm\" target=\"_blank\">",
"      file://dpd.cdc.gov/dpdx/html/Echinostomiasis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9032=[""].join("\n");
var outline_f8_52_9032=null;
var title_f8_52_9033="Novel therapies for the acute respiratory distress syndrome";
var content_f8_52_9033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Novel therapies for the acute respiratory distress syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9033/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9033/contributors\">",
"     Mark D Siegel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9033/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9033/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9033/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/52/9033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most current therapies for acute respiratory distress syndrome (ARDS) are supportive, aimed at improving gas exchange and preventing complications while the underlying condition that precipitated the ARDS is addressed. Potential therapies for ARDS are being evaluated in an attempt to improve clinical outcomes; however, none are currently recommended as routine therapy because patient-important effects are uncertain. Potential explanations for this uncertainty include inconsistent evidence, imprecise estimates of effect, and the enrollment of heterogeneous populations in clinical trials.",
"   </p>",
"   <p>",
"    The Berlin Definition of ARDS (published in 2012) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/1\">",
"     1",
"    </a>",
"    ] has replaced the American-European Consensus Conference&rsquo;s definition of ARDS (published in 1994) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The Berlin Definition may assist future trials of novel treatments by improving diagnostic reliability and allowing more precise stratification of patients according to severity. However, it should be recognized that most existing evidence is based upon prior definitions. The current diagnostic criteria for ARDS are provided separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link&amp;anchor=H10171195#H10171195\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential therapies for ARDS that are currently being investigated are reviewed here. The supportive care, mechanical ventilation, clinical features, diagnosis, prognosis, etiology, and pathophysiology of ARDS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=see_link\">",
"     \"Supportive care and oxygenation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=see_link\">",
"     \"Mechanical ventilation in acute respiratory distress syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"     \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=see_link\">",
"     \"Acute respiratory distress syndrome: Prognosis and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"     \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SURFACTANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surfactant therapy is not used to treat adults with ARDS because the evidence regarding its effect on patient-important outcomes is inconsistent. Examples of the conflicting data include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Numerous randomized trials found no clinical benefit from recombinant surfactant protein C, synthetic surfactant, or freeze dried natural animal surfactant in patients with ARDS [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/4-8\">",
"       4-8",
"      </a>",
"      ]. When these trials were pooled in a meta-analysis, there was again no improvement in mortality (odds ratio 0.97, 95% CI 0.73-1.30) despite a trend toward improved oxygenation (mean difference +13.18 mmHg, 95% CI, -2.95 - +29.32 mmHg) among patients treated exogenous surfactant [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a trial that randomly assigned 153 infants, children, and adolescents to intratracheal",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2707?source=see_link\">",
"       calfactant",
"      </a>",
"      (a type of exogenous surfactant) or placebo demonstrated decreased mortality (19 versus 33 percent for placebo) and more rapid improvement of oxygenation among patients who received calfactant [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/10\">",
"       10",
"      </a>",
"      ]. A similar trial of intratracheal calfactant in adults is in progress [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been suggested that the inconsistent results may reflect differences in the formulation (ie, types and amounts of protein and phospholipid) of surfactant, population studied (ie, severity of illness, adults or children), method of drug delivery, dose, concurrent ventilation strategy, or inactivation of the delivered agent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. However, when differences in the formulation were evaluated by a meta-analysis, there were no differences in mortality when surfactant with surface protein was compared to surfactant without surface protein [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/9\">",
"     9",
"    </a>",
"    ]. When differences in the severity of illness were investigated by a meta-analysis, it was found that recombinant surfactant protein C improved oxygenation and decreased mortality (26.3 versus 39.3 percent, adjusted odds ratio 0.30, 95% CI 0.11-0.82) in the subgroup of patients who had severe ARDS due to pneumonia or aspiration, but not in the overall ARDS population [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/15\">",
"     15",
"    </a>",
"    ]. A subsequent trial designed to evaluate surfactant therapy in this subgroup was inconclusive because of a methodological flaw (the resuspension process partially inactivated the surfactant) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/16\">",
"     16",
"    </a>",
"    ]. Therefore, the reasons for the inconsistent results remain unknown.",
"   </p>",
"   <p>",
"    The idea of using exogenous surfactant therapy to treat patients with ARDS is based upon several observations. First, the major purpose of endogenous surfactant is to prevent atelectasis. Second, multiple surfactant abnormalities (composition and function) have been described in patients with ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/17-19\">",
"     17-19",
"    </a>",
"    ] and may be exacerbated by mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/14\">",
"     14",
"    </a>",
"    ]. And, finally, atelectasis is a major contributor to hypoxemia and the propagation of lung injury in ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/20\">",
"     20",
"    </a>",
"    ]. The aim of exogenous surfactant therapy is to mitigate or eliminate atelectasis caused by insufficient or abnormal surfactant by administering functional surfactant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=see_link\">",
"     \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=see_link\">",
"     \"Ventilator-associated lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3172453\">",
"    <span class=\"h1\">",
"     ANTIOXIDANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antioxidant therapy with dietary oil supplementation has not become routine therapy for adults with ARDS due to inconsistent evidence. The basis of the hypothesis that antioxidant therapy might be beneficial in patients with ARDS are the observations that reactive oxygen species and partial depletion of antioxidant defense appear to be important in the establishment and propagation of ARDS, as well as evidence that indices of oxidative stress are higher among non-survivors than survivors of ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of the conflicting data regarding dietary oil supplementation include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Favoring dietary oil supplementation, a trial that randomly assigned 98 patients with ARDS to receive standard tube feeds or a combination of eicosapentaenoic acid (EPA) and gamma-linolenic acid (GLA) found that the patients who received EPA and GLA required fewer days of ventilatory support and fewer days in the ICU [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/22\">",
"       22",
"      </a>",
"      ]. Moreover, another trial that randomly assigned 100 patients with ARDS to receive standard tube feeds or a combination of EPA and GLA found that patients who received EPA and GLA had better oxygenation and required a shorter duration of mechanical ventilation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Arguing against dietary oil supplementation, more recent trials have found no effect from supplementation with dietary oils. One trial comparing a combination of omega-3 fatty acids, GLA, and antioxidants to placebo was terminated due to futility [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/24\">",
"       24",
"      </a>",
"      ], while another trial comparing EPA plus docosahexanoic acid to saline placebo found no difference in clinical outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further research is needed to better understand whether the conflicting results are due to the study designs (ie, different controls), different combinations of dietary supplements, or different doses of dietary supplements.",
"   </p>",
"   <p>",
"    In addition to dietary oil supplementation, two other antioxidant therapies have been studied. Lisophylline (1-[5R-hydroxyhexyl]-3,7-dimethylxanthine) is an agent that decreases circulating fatty acids, which have been shown to increase several-fold in patients with ARDS and act as proinflammatory mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Despite promising animal data, a randomized trial comparing lisophylline to placebo in adults with ARDS was stopped after the enrollment of 235 patients because an interim analysis showed no difference in survival or other clinical end points [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/27\">",
"     27",
"    </a>",
"    ]. N-acetylcysteine and L-2-oxothiazolidine-4-carboxylate (Procysteine) are agents that restore glutathione, an important antioxidant. While a trial confirmed that these therapies restored glutathione stores [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/28\">",
"     28",
"    </a>",
"    ], they did not decrease the production of reactive oxygen species and they had little effect on physiological or patient-important outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14351419\">",
"     'Ineffective or harmful therapies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3172460\">",
"    <span class=\"h1\">",
"     GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocyte-monocyte colony stimulating factor (gm-CSF) has not become routine therapy for adults with ARDS because the evidence is still inconclusive. As an example, in a trial that randomly assigned 131 patients with ARDS to receive either intravenous gm-CSF or placebo for 14 days, patients who received gm-CSF had lower mortality (17 versus 23 percent) and more organ failure-free days (15.7 versus 12.8 days) than patients who received placebo, but these differences were not statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/31\">",
"     31",
"    </a>",
"    ]. These findings indicate that larger trials with more events are necessary to confirm or exclude these effects. There was no difference in the number of ventilator-free days.",
"   </p>",
"   <p>",
"    The hypothesis that granulocyte-monocyte colony stimulating factor (gm-CSF) may be beneficial to patients with ARDS is based upon the observation that increased gm-CSF in the bronchoalveolar lavage fluid of humans with ARDS is associated with better survival [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, animal studies have found that gm-CSF limits epithelial cell injury and maintains alveolar macrophage function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INHALED VASODILATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled vasodilators (eg, nitric oxide, prostacyclin, prostaglandin E1) selectively dilate the vessels that perfuse well-ventilated lung zones, resulting in improved oxygenation due to better",
"    <span class=\"nowrap\">",
"     ventilation/perfusion",
"    </span>",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    matching and the amelioration of pulmonary hypertension (",
"    <a class=\"graphic graphic_figure graphicRef56760 \" href=\"UTD.htm?11/36/11853\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/35\">",
"     35",
"    </a>",
"    ]. Inhaled vasodilators have few systemic effects and rarely cause systemic hypotension since they act locally and have short half-lives.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5274368\">",
"    <span class=\"h2\">",
"     Nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine inhaled nitric oxide (NO) has not become routine therapy for adults with ARDS because, although it improves oxygenation, it has not been shown to reduce morbidity or mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. Instead, inhaled NO should be reserved for patients with intractable, life-threatening hypoxemia despite conventional management [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evidence is best illustrated by two meta-analyses (each with over 1200 patients) that compared inhaled NO to either placebo or conventional management [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Both studies found that inhaled NO induced a modest, transient improvement in oxygenation, without any improvement in mortality, duration of mechanical ventilation, or ventilator-free days.",
"    <br/>",
"    <br/>",
"    While the major effect of inhaled NO appears to be improved oxygenation, oxygenation does not improve in all patients who receive inhaled NO [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/35,41\">",
"     35,41",
"    </a>",
"    ]. The factors that determine responsiveness are uncertain, but several have been suggested retrospective cohort studies. Patients without sepsis or septic shock may respond to inhaled NO more frequently than patients with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/42\">",
"     42",
"    </a>",
"    ]. In addition, high baseline pulmonary vascular resistance and responsiveness to positive end-expiratory pressure (PEEP) may predict a response in inhaled NO [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although published guidelines endorse monitoring methemoglobin concentrations when inhaled nitric oxide is given, the risk of methemoglobinemia is rare when typical doses are used and appears to be limited to patients with methemoglobin reductase deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. A meta-analysis found that inhaled NO increased the risk of renal impairment (relative risk 1.59, 95% CI 1.17 to 2.16), but did not increase the risk of bleeding, methemoglobin formation, or nitrogen dioxide formation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/46\">",
"     46",
"    </a>",
"    ]. The lack of proven outcome benefits and risk of renal impairment argue against the use of inhaled nitric oxide in settings other than refractory hypoxemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prostacyclin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine inhaled prostacyclin has not become routine therapy for adults with ARDS because it has not been shown to improve patient-important outcomes, despite the consistent finding that it is associated with an improvement in oxygenation and a decrease in pulmonary arterial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/47-53\">",
"     47-53",
"    </a>",
"    ]. These effects are comparable to those associated with inhaled NO (",
"    <a class=\"graphic graphic_figure graphicRef57304 graphicRef67293 \" href=\"UTD.htm?27/10/27823\">",
"     figure 2A-B",
"    </a>",
"    ). Inhaled prostacyclin should be reserved for patients with intractable, life-threatening hypoxemia despite conventional management.",
"   </p>",
"   <p>",
"    The major advantage of inhaled prostacyclin compared with inhaled NO is that inhaled prostacyclin does not require sophisticated equipment for administration. Clinical experience with inhaled prostacyclin for ARDS suggests that adverse effects are infrequent, although published data are limited [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ANTI-INFLAMMATORY THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients who succumb to ARDS do not die from respiratory failure, but rather from complications of a prolonged stay in the intensive care unit (ICU) such as nosocomial infection or multiple organ dysfunction syndrome (MODS) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/49\">",
"     49",
"    </a>",
"    ]. Persistent inflammation may contribute to these complications and is associated with poor outcomes from ARDS; as an example, mortality is higher among patients who have large quantities of neutrophils and proinflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    low levels of anti-inflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/56\">",
"     56",
"    </a>",
"    ]. Based upon these observations, it has been hypothesized that anti-inflammatory medications might improve the outcome of ARDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of glucocorticoids in the management of ARDS is a source of ongoing controversy. Systemic glucocorticoids clearly have a role in situations when ARDS has been precipitated by a steroid-responsive process (eg, acute eosinophilic pneumonia) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/57\">",
"     57",
"    </a>",
"    ]. However, systemic glucocorticoid therapy has not become routine therapy for adults with other types of ARDS because its effect on mortality is uncertain and it tends to cause important side effects.",
"   </p>",
"   <p>",
"    The uncertain effect of glucocorticoids on mortality is exemplified by four meta-analyses that compared systemic glucocorticoid therapy to placebo in patients with ARDS. One meta-analysis found that glucocorticoid therapy reduced mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/58\">",
"     58",
"    </a>",
"    ]. However, the other three meta-analyses reported a reduction of mortality that did not reach statistical significance, indicating that larger trials with more events are necessary to either confirm or exclude an effect on mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Regarding other patient-important outcomes, the meta-analyses found that glucocorticoid therapy improved gas exchange, decreased the duration of mechanical ventilation, and decreased the length of stay in the ICU [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/58,59,61\">",
"     58,59,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that the effects of systemic glucocorticoids vary according to when they are initiated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late: Several studies have evaluated the impact of systemic glucocorticoids during persistent ARDS, also known as the fibroproliferative phase of ARDS or late ARDS. The most notable was a double-blind trial by the ARDS Network that randomly assigned 180 patients with persistent ARDS (defined as ongoing disease 7 to 28 days after its onset) to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      or placebo for 21 days [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/62\">",
"       62",
"      </a>",
"      ]. Overall, there was no difference in 60-day mortality or 180-day mortality. However, there were important differences when the patients were divided according to when they received glucocorticoid therapy. In the subgroup of patients randomized 7 to 13 days after the onset of ARDS, methylprednisolone caused a non-statistically significant reduction in 60-day mortality (27 versus 36 percent) and 180-day mortality (27 versus 39 percent). In contrast, among patients randomized more than 14 days after the onset of ARDS, methylprednisolone increased 60-day mortality (35 versus 8 percent) and 180-day mortality (44 versus 12 percent). Methylprednisolone increased ventilator-free days, shock-free days, oxygenation, lung compliance, and blood pressure, but also increased neuromuscular weakness.",
"     </li>",
"     <li>",
"      Early: Other clinical trials addressed the possibility that systemic glucocorticoids might be effective when given early in ARDS. In a double-blind trial, patients with early ARDS (defined as &le;72 hours) were randomly assigned in a 2:1 ratio to receive glucocorticoid therapy (n = 63) or placebo (n = 28) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/63\">",
"       63",
"      </a>",
"      ]. Patients in the glucocorticoid group were given",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      at 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for up to 28 days. Important features of this trial included vigilant surveillance for infection and avoidance of neuromuscular blockade. Glucocorticoid therapy reduced the duration of mechanical ventilation, length of ICU stay, and ICU mortality (21 versus 43 percent). The results of this trial are provocative, but not definitive, given the trial's small size and imbalances in the treatment arms (including a larger number of patients with catecholamine-dependent shock in the placebo group).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data indicate that systemic glucocorticoid therapy should NOT be initiated 14 days or longer after the onset of ARDS and the impact of earlier therapy on mortality is uncertain. Larger trials are indicated to resolve the uncertainty regarding the effect of early systemic glucocorticoid therapy in ARDS.",
"   </p>",
"   <p>",
"    The major adverse effects of systemic glucocorticoids are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4791827\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statins have not become routine therapy for adults with ARDS because they have not been shown to improve patient-important outcomes. The original idea that statin therapy might be beneficial to patients with ARDS was based upon studies that found that statins reduced the concentration of proinflammatory cytokines, reduced the inflammatory infiltrate in the interstitium, and improved survival in animal models. However, in a subsequent trial that randomly assigned 60 patients with ARDS to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    or placebo for 14 days or until either the cessation of mechanical ventilation, the simvastatin group had non-statistically significant improvement in oxygenation and airway plateau pressure, but no change in mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/64\">",
"     64",
"    </a>",
"    ]. A randomized trial comparing simvastatin to placebo in patients at risk for ARDS was terminated due to minimal enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15316065\">",
"    <span class=\"h2\">",
"     Macrolide antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrolide antibiotics have both antimicrobial and anti-inflammatory effects, and animal models suggest that these agents may have a beneficial effect in ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. To evaluate the effects of macrolide antibiotics in humans with ARDS, an observational study was conducted using data from the Lisofylline and Respiratory Management of Acute Lung Injury (LARMA) randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/27\">",
"     27",
"    </a>",
"    ]. In the observational study, 47 patients with ARDS who received a macrolide antibiotic within the initial 24 hours were compared with 188 patients who did not [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/68\">",
"     68",
"    </a>",
"    ]. There was a trend toward less 180-day mortality among patients who received a macrolide antibiotic (23 versus 36 percent); after adjusting for potential confounders (eg, patients who received a macrolide antibiotic were less likely to have received low tidal volume ventilation), the lower 180-day mortality became statistically significant (hazard ratio 0.46, 95% CI 0.23-0.92). This preliminary evidence warrants further evaluation with a controlled clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21399541\">",
"    <span class=\"h1\">",
"     BETA AGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown that beta agonists improve physiological outcomes in patients with ARDS [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. As an example, a trial that randomly assigned 40 patients with ARDS to receive intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    (15",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per hour) or placebo for seven days found that intravenous albuterol was associated with less lung water (9 versus 13",
"    <span class=\"nowrap\">",
"     mL/kg)",
"    </span>",
"    and a lower plateau airway pressure (24 versus 30 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/73\">",
"     73",
"    </a>",
"    ]. Inhaled albuterol was not studied in the trial.",
"   </p>",
"   <p>",
"    Such promising physiological evidence prompted several clinical trials to measure patient-important outcomes. One trial randomly assigned 282 patients with ARDS to receive aerosolized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    (5 mg) or placebo every four hours for up to ten days [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/74\">",
"     74",
"    </a>",
"    ]. No differences in the mean number of ventilator-free days or hospital mortality were detected. Heart rates were higher in the albuterol group, but there was no difference in the frequency of dysrhythmias. Another trial randomly assigned 326 patients to receive intravenous salbutamol or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/75\">",
"     75",
"    </a>",
"    ]. The trial was terminated due to increased mortality among patients receiving salbutamol.",
"   </p>",
"   <p>",
"    While these studies indicate that beta agonists do not have a direct beneficial effect on ARDS per se, they are effective agents for treating bronchospasm in patients who have ARDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14351419\">",
"    <span class=\"h1\">",
"     INEFFECTIVE OR HARMFUL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of potential therapies for ARDS were once regarded as promising, but have since proven to be either ineffective or harmful. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      N-acetylcysteine [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Procysteine (L-2-oxothiazolidine-4-carboxylate) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/29\">",
"       29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lisophylline [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/27\">",
"       27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Intravenous prostaglandin E1 [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/76,77\">",
"       76,77",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Neutrophil elastase inhibitors [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/78\">",
"       78",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       Ibuprofen",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/79\">",
"       79",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Activated protein C [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/80\">",
"       80",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9033/abstract/81-85\">",
"       81-85",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=see_link\">",
"       \"Patient information: Adult respiratory distress syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most current therapies for acute respiratory distress syndrome (ARDS) are supportive, aimed at improving gas exchange and preventing complications while the underlying condition that precipitated the ARDS is addressed. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential therapies for ARDS are being evaluated in an attempt to improve clinical outcomes in ARDS; however, these therapies have not become routine in adults with ARDS because either there are physiological benefits without definitive patient-important benefits or the patient-important effects are uncertain (due to inconsistent evidence or imprecise estimates of effect) (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Inhaled nitric oxide, inhaled prostacyclin, and inhaled prostaglandin E1 improve physiologic parameters (eg, oxygenation) in patients with ARDS, but do not appear to improve patient-important outcomes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Inhaled vasodilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exogenous surfactant therapy and antioxidant therapy via dietary oil supplementation are characterized by conflicting evidence. Additional studies are necessary to sort out the true effects of these therapies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Surfactant'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3172453\">",
"       'Antioxidants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While the effects of systemic glucocorticoids administered within the first two weeks of ARDS are uncertain and require further study, systemic glucocorticoids administered two weeks or later appear to be harmful. We suggest NOT administering systemic glucocorticoids to patients 14 days or longer after the onset of ARDS (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of potential therapies were once regarded as promising in patients with ARDS, but have since proven to be either ineffective or harmful. These include beta agonists, N-acetylcysteine, procysteine, lisophylline, intravenous prostaglandin E1, neutrophile elastase inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"       ketoconazole",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"       ibuprofen",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H14351419\">",
"       'Ineffective or harmful therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/1\">",
"      Anonymous. Acute respiratory distress syndrome: The Berlin definition. JAMA 2012; 307:2526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/2\">",
"      Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/3\">",
"      Artigas A, Bernard GR, Carlet J, et al. The American-European Consensus Conference on ARDS, part 2: Ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/4\">",
"      Weg JG, Balk RA, Tharratt RS, et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994; 272:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/5\">",
"      Spragg RG, Lewis JF, Wurst W, et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003; 167:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/6\">",
"      Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N Engl J Med 1996; 334:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/7\">",
"      Spragg RG, Lewis JF, Walmrath HD, et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004; 351:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/8\">",
"      Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/9\">",
"      Davidson WJ, Dorscheid D, Spragg R, et al. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care 2006; 10:R41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/10\">",
"      Willson DF, Thomas NJ, Markovitz BP, et al. Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: a randomized controlled trial. JAMA 2005; 293:470.",
"     </a>",
"    </li>",
"    <li>",
"     Calfactant for Direct Acute Respiratory Distress Syndrome (CARDS) file://clinicaltrials.gov/show/NCT00682500 (Accessed on February 07, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/12\">",
"      Kerr CL, Ito Y, Manwell SE, et al. Effects of surfactant distribution and ventilation strategies on efficacy of exogenous surfactant. J Appl Physiol 1998; 85:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/13\">",
"      Ito Y, Manwell SE, Kerr CL, et al. Effects of ventilation strategies on the efficacy of exogenous surfactant therapy in a rabbit model of acute lung injury. Am J Respir Crit Care Med 1998; 157:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/14\">",
"      Albert RK. The role of ventilation-induced surfactant dysfunction and atelectasis in causing acute respiratory distress syndrome. Am J Respir Crit Care Med 2012; 185:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/15\">",
"      Taut FJ, Rippin G, Schenk P, et al. A Search for subgroups of patients with ARDS who may benefit from surfactant replacement therapy: a pooled analysis of five studies with recombinant surfactant protein-C surfactant (Venticute). Chest 2008; 134:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/16\">",
"      Spragg RG, Taut FJ, Lewis JF, et al. Recombinant surfactant protein C-based surfactant for patients with severe direct lung injury. Am J Respir Crit Care Med 2011; 183:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/17\">",
"      Zimmerman JJ. Surfactant is a target during acute lung injury inflammation. Crit Care Med 1996; 24:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/18\">",
"      Hallman M, Spragg R, Harrell JH, et al. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982; 70:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/19\">",
"      Gregory, TJ, Longmore, WJ, Moxley, MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/20\">",
"      Gattinoni L, Presenti A, Torresin A, et al. Adult respiratory distress syndrome profiles by computed tomography. J Thorac Imaging 1986; 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/21\">",
"      Quinlan GJ, Lamb NJ, Tilley R, et al. Plasma hypoxanthine levels in ARDS: implications for oxidative stress, morbidity, and mortality. Am J Respir Crit Care Med 1997; 155:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/22\">",
"      Gadek JE, DeMichele SJ, Karlstad MD, et al. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome. Enteral Nutrition in ARDS Study Group. Crit Care Med 1999; 27:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/23\">",
"      Singer P, Theilla M, Fisher H, et al. Benefit of an enteral diet enriched with eicosapentaenoic acid and gamma-linolenic acid in ventilated patients with acute lung injury. Crit Care Med 2006; 34:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/24\">",
"      Rice TW, Wheeler AP, Thompson BT, et al. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury. JAMA 2011; 306:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/25\">",
"      Stapleton RD, Martin TR, Weiss NS, et al. A phase II randomized placebo-controlled trial of omega-3 fatty acids for the treatment of acute lung injury. Crit Care Med 2011; 39:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/26\">",
"      Bursten SL, Federighi DA, Parsons P, et al. An increase in serum C18 unsaturated free fatty acids as a predictor of the development of acute respiratory distress syndrome. Crit Care Med 1996; 24:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/27\">",
"      Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/28\">",
"      Laurent T, Markert M, Feihl F, et al. Oxidant-antioxidant balance in granulocytes during ARDS. Effect of N-acetylcysteine. Chest 1996; 109:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/29\">",
"      Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. The Antioxidant in ARDS Study Group. Chest 1997; 112:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/30\">",
"      Jepsen S, Herlevsen P, Knudsen P, et al. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med 1992; 20:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/31\">",
"      Paine R 3rd, Standiford TJ, Dechert RE, et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 2012; 40:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/32\">",
"      Matute-Bello G, Liles WC, Radella F 2nd, et al. Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome. Crit Care Med 2000; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/33\">",
"      Paine R 3rd, Wilcoxen SE, Morris SB, et al. Transgenic overexpression of granulocyte macrophage-colony stimulating factor in the lung prevents hyperoxic lung injury. Am J Pathol 2003; 163:2397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/34\">",
"      Baleeiro CE, Christensen PJ, Morris SB, et al. GM-CSF and the impaired pulmonary innate immune response following hyperoxic stress. Am J Physiol Lung Cell Mol Physiol 2006; 291:L1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/35\">",
"      Rossaint R, Falke KJ, L&oacute;pez F, et al. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med 1993; 328:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/36\">",
"      Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA 2004; 291:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/37\">",
"      Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med 1998; 26:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/38\">",
"      Adhikari NK, Burns KE, Friedrich JO, et al. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 2007; 334:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/39\">",
"      Afshari A, Brok J, M&oslash;ller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesth Analg 2011; 112:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/40\">",
"      Pipeling MR, Fan E. Therapies for refractory hypoxemia in acute respiratory distress syndrome. JAMA 2010; 304:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/41\">",
"      Rossaint R, Gerlach H, Schmidt-Ruhnke H, et al. Efficacy of inhaled nitric oxide in patients with severe ARDS. Chest 1995; 107:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/42\">",
"      Manktelow C, Bigatello LM, Hess D, Hurford WE. Physiologic determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndrome. Anesthesiology 1997; 87:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/43\">",
"      Puybasset L, Rouby JJ, Mourgeon E, et al. Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure. Am J Respir Crit Care Med 1995; 152:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/44\">",
"      Puri N, Dellinger RP. Inhaled nitric oxide and inhaled prostacyclin in acute respiratory distress syndrome: what is the evidence? Crit Care Clin 2011; 27:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/45\">",
"      Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med 2005; 353:2683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/46\">",
"      Afshari A, Brok J, M&oslash;ller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev 2010; :CD002787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/47\">",
"      Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/48\">",
"      Walmrath D, Schneider T, Schermuly R, et al. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996; 153:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/49\">",
"      Ferring M, Vincent JL. Is outcome from ARDS related to the severity of respiratory failure? Eur Respir J 1997; 10:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/50\">",
"      Royston D. Inhalational agents for pulmonary hypertension. Lancet 1993; 342:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/51\">",
"      van Heerden PV, Barden A, Michalopoulos N, et al. Dose-response to inhaled aerosolized prostacyclin for hypoxemia due to ARDS. Chest 2000; 117:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/52\">",
"      Domenighetti G, Stricker H, Waldispuehl B. Nebulized prostacyclin (PGI2) in acute respiratory distress syndrome: impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response. Crit Care Med 2001; 29:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/53\">",
"      Afshari A, Brok J, M&oslash;ller AM, Wetterslev J. Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Cochrane Database Syst Rev 2010; :CD007733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/54\">",
"      Headley AS, Tolley E, Meduri GU. Infections and the inflammatory response in acute respiratory distress syndrome. Chest 1997; 111:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/55\">",
"      Steinberg KP, Milberg JA, Martin TR, et al. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/56\">",
"      Donnelly SC, Strieter RM, Reid PT, et al. The association between mortality rates and decreased concentrations of interleukin-10 and interleukin-1 receptor antagonist in the lung fluids of patients with the adult respiratory distress syndrome. Ann Intern Med 1996; 125:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/57\">",
"      Davis WB, Wilson HE, Wall RL. Eosinophilic alveolitis in acute respiratory failure. A clinical marker for a non-infectious etiology. Chest 1986; 90:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/58\">",
"      Tang BM, Craig JC, Eslick GD, et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care Med 2009; 37:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/59\">",
"      Meduri GU, Marik PE, Chrousos GP, et al. Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008; 34:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/60\">",
"      Agarwal R, Nath A, Aggarwal AN, Gupta D. Do glucocorticoids decrease mortality in acute respiratory distress syndrome? A meta-analysis. Respirology 2007; 12:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/61\">",
"      Peter JV, John P, Graham PL, et al. Corticosteroids in the prevention and treatment of acute respiratory distress syndrome (ARDS) in adults: meta-analysis. BMJ 2008; 336:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/62\">",
"      Steinberg KP, Hudson LD, Goodman RB, et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/63\">",
"      Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007; 131:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/64\">",
"      Craig TR, Duffy MJ, Shyamsundar M, et al. A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med 2011; 183:620.",
"     </a>",
"    </li>",
"    <li>",
"     Simvastatin Effect on the Incidence of Acute Lung Injury/Adult Respiratory Distress Syndrome (ALI/ARDS) file://www.clinicaltrials.gov/ct2/show/NCT01195428 (Accessed on February 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/66\">",
"      Kawashima M, yatsunami J, Fukuno Y, et al. Inhibitory effects of 14-membered ring macrolide antibiotics on bleomycin-induced acute lung injury. Lung 2002; 180:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/67\">",
"      Leiva M, Ruiz-Bravo A, Jimenez-Valera M. Effects of telithromycin in in vitro and in vivo models of lipopolysaccharide-induced airway inflammation. Chest 2008; 134:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/68\">",
"      Walkey AJ, Wiener RS. Macrolide antibiotics and survival in patients with acute lung injury. Chest 2012; 141:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/69\">",
"      Sakuma T, Okaniwa G, Nakada T, et al. Alveolar fluid clearance in the resected human lung. Am J Respir Crit Care Med 1994; 150:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/70\">",
"      Sakuma T, Suzuki S, Usuda K, et al. Preservation of alveolar epithelial fluid transport mechanisms in rewarmed human lung after severe hypothermia. J Appl Physiol 1996; 80:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/71\">",
"      Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med 2002; 346:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/72\">",
"      Perkins GD, Gao F, Thickett DR. In vivo and in vitro effects of salbutamol on alveolar epithelial repair in acute lung injury. Thorax 2008; 63:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/73\">",
"      Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): a randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006; 173:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/74\">",
"      National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Matthay MA, Brower RG, et al. Randomized, placebo-controlled clinical trial of an aerosolized &beta;���-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011; 184:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/75\">",
"      Gao Smith F, Perkins GD, Gates S, et al. Effect of intravenous &beta;-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012; 379:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/76\">",
"      Bone RC, Slotman G, Maunder R, et al. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. Prostaglandin E1 Study Group. Chest 1989; 96:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/77\">",
"      Abraham E, Baughman R, Fletcher E, et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group. Crit Care Med 1999; 27:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/78\">",
"      Zeiher BG, Artigas A, Vincent JL, et al. Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study. Crit Care Med 2004; 32:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/79\">",
"      Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/80\">",
"      Liu KD, Levitt J, Zhuo H, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/81\">",
"      Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. The ARDS Network. JAMA 2000; 283:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/82\">",
"      Slotman GJ, Burchard KW, D'Arezzo A, Gann DS. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma 1988; 28:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/83\">",
"      Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993; 21:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/84\">",
"      Sinuff T, Cook DJ, Peterson JC, Fuller HD. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. J Crit Care 1999; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9033/abstract/85\">",
"      Williams JG, Maier RV. Ketoconazole inhibits alveolar macrophage production of inflammatory mediators involved in acute lung injury (adult respiratory distress syndrome). Surgery 1992; 112:270.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1618 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9033=[""].join("\n");
var outline_f8_52_9033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SURFACTANT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3172453\">",
"      ANTIOXIDANTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3172460\">",
"      GRANULOCYTE-MONOCYTE COLONY STIMULATING FACTOR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INHALED VASODILATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5274368\">",
"      Nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prostacyclin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ANTI-INFLAMMATORY THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4791827\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15316065\">",
"      Macrolide antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21399541\">",
"      BETA AGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14351419\">",
"      INEFFECTIVE OR HARMFUL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1618\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1618|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/36/11853\" title=\"figure 1\">",
"      Effect of inhaled vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/50/3886\" title=\"figure 2A\">",
"      Effect of PGI2 and NO on PaO2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/39/11902\" title=\"figure 2B\">",
"      Effect of PGI2 and NO on PVR",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4871?source=related_link\">",
"      Acute respiratory distress syndrome: Prognosis and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/42/2730?source=related_link\">",
"      Mechanical ventilation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/14/4322?source=related_link\">",
"      Patient information: Adult respiratory distress syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9065?source=related_link\">",
"      Supportive care and oxygenation in acute respiratory distress syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16182?source=related_link\">",
"      Ventilator-associated lung injury",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_52_9034="Approach to the adult patient with syncope in the emergency department";
var content_f8_52_9034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult patient with syncope in the emergency department",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9034/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9034/contributors\">",
"     Daniel McDermott, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9034/contributors\">",
"     James Quinn, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9034/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9034/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/52/9034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/52/9034/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/52/9034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope is a transient loss of consciousness, associated with loss of postural tone, with spontaneous return to baseline neurologic function requiring no resuscitative efforts. The underlying mechanism is global hypoperfusion of both the cerebral cortices or focal hypoperfusion of the reticular activating system.",
"   </p>",
"   <p>",
"    Syncope is a common complaint in the emergency department (ED), accounting for one to three percent of all ED visits and hospital admissions in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Although most potential causes are benign and self-limited, others are associated with significant morbidity and mortality. The differential diagnosis is broad, and management focuses on the underlying cause when this is discernible. During ED evaluation, however, the cause of syncope often remains unclear and management must focus on risk stratification to differentiate among patients safe for discharge and those who require emergent investigation and in-hospital management. Near syncope (ie, near loss of consciousness) and true syncope are considered a spectrum of the same symptom, and clinicians should approach them in similar fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss how to evaluate and manage patients presenting to the ED with syncope. Detailed discussions of specific types of syncope and the evaluation of syncope in children and adults are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"     \"Pathogenesis and etiology of syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"     \"Reflex syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=see_link\">",
"     \"Emergent evaluation of syncope in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Syncope has many causes, which are often difficult to determine in the emergency department (ED). Several studies show that clinicians, after reviewing the history, examination findings, and the ECG, establish the underlying diagnosis about 50 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Often, patients remain undiagnosed, despite exhaustive diagnostic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Tables listing the most dangerous and most common etiologies of syncope are provided (",
"    <a class=\"graphic graphic_table graphicRef81820 \" href=\"UTD.htm?6/36/6732\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef62074 \" href=\"UTD.htm?42/56/43915\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Life-threatening conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary responsibility of the emergency clinician is to assess whether a life-threatening cause of syncope is present, and to provide appropriate management and disposition. The most important causes to consider are: cardiac syncope, blood loss, pulmonary embolism, and subarachnoid hemorrhage. Other conditions, such as seizure, stroke, and head injury, do not meet the technical definition of syncope but should be considered during the initial assessment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac syncope &ndash; Cardiac causes are the most common life-threatening conditions associated with syncope. They include arrhythmia, ischemia,",
"      <span class=\"nowrap\">",
"       structural/valvular",
"      </span>",
"      abnormalities (eg, aortic stenosis), cardiac tamponade, and pacemaker malfunction. Studies of short term and one year outcomes following syncope found patients with cardiac syncope to be at significant risk for sudden death [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/2,9\">",
"       2,9",
"      </a>",
"      ]. Patients with syncope and a history of heart failure are at even greater risk [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathogenesis and etiology of syncope\", section on 'Causes of syncope'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28855?source=see_link&amp;anchor=H2#H2\">",
"       \"Management of the patient with syncope\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hemorrhage &ndash; Large blood loss, particularly acute severe hemorrhage, can manifest as syncope. Important potential causes include: trauma, gastrointestinal bleeding, ruptured aortic aneurysm, ruptured ovarian cyst, ruptured ectopic pregnancy, and ruptured spleen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link\">",
"       \"Initial evaluation and management of shock in adult trauma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link\">",
"       \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link\">",
"       \"Evaluation and management of ruptured ovarian cyst\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/54/1898?source=see_link\">",
"       \"Management of splenic injury in the adult trauma patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=see_link&amp;anchor=H53322839#H53322839\">",
"       \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\", section on 'Introduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary embolism &ndash; Hemodynamically significant pulmonary embolism is an uncommon but well documented cause of syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"       \"Diagnosis of acute pulmonary embolism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subarachnoid hemorrhage &ndash; Patients presenting with syncope following a headache require evaluation for a possible subarachnoid hemorrhage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"       \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurocardiogenic syncope &ndash; Often referred to as vasovagal or vasodepressor syncope, neurocardiogenic syncope is the most common cause of syncope, accounting for 25 to 65 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients diagnosed with neurocardiogenic syncope have an excellent prognosis with no increase in mortality or morbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/12\">",
"       12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Autonomic activation causes neurocardiogenic syncope. Three types of responses are seen: a cardioinhibitory response, a vasodepressor response, and a mixed response with features of both. Significant bradycardia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypotension accompany the acute loss of consciousness. Potential triggers are numerous and often determination of the underlying cause is made in the outpatient setting. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"       \"Reflex syncope\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Most patients with neurocardiogenic syncope experience a prodrome, which may include dizziness or lightheadedness, a sense of warmth, pallor,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      abdominal pain, and diaphoresis, prior to their loss of consciousness. Examples include micturition or defecation syncope, situational syncope (eg, while having blood drawn), or cough-mediated syncope.",
"     </li>",
"     <li>",
"      Carotid sinus hypersensitivity &ndash; Carotid sinus hypersensitivity is a variant of neurocardiogenic syncope, resulting from pressure at the carotid sinus. External pressure to the neck can induce this reflex response. Common causes include shaving, a tight collar, and turning of the head. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=see_link\">",
"       \"Carotid sinus hypersensitivity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Orthostasis &ndash; Orthostatic syncope comprises between 5 and 24 percent of syncope cases and can be defined by a drop in blood pressure of more than 20 mmHg, or a reflex tachycardia of more than 20 beats per minute. Orthostasis is most often caused by a loss of intravascular volume, from any number of causes, or by failure or instability of the autonomic nervous system. Nevertheless, clinicians should remain cautious because orthostasis can occur with cardiac syncope. Syncope from orthostatic hypotension is a diagnosis of exclusion in the emergency department, reserved for low risk patients who have symptoms consistent with the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=see_link\">",
"       \"Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Orthostatic vital signs are neither sensitive nor specific in assessing volume status or diagnosing syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. Many patients become symptomatic if their systolic blood pressure drops below 90 mmHg, but a large portion of the population who meets the definition of orthostasis do not have syncope. Elders, pregnant women, and patients taking drugs with vasodilating effects are predisposed to develop symptomatic orthostasis.",
"     </li>",
"     <li>",
"      Medications &ndash; The effects of medications account for 5 to 15 percent of syncopal events. The mechanism can be orthostasis or cardiotoxicity. Medications often implicated include calcium channel blockers, beta blockers, alpha blockers, nitrates, antiarrhythmics, diuretics (affecting volume status and electrolyte concentrations), and medications affecting the QTc interval (eg, antipsychotics and antiemetics) (",
"      <a class=\"graphic graphic_table graphicRef62074 \" href=\"UTD.htm?42/56/43915\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic syncope &ndash; True syncope is defined by an immediate, spontaneous return to baseline function following loss of consciousness, without new focal neurologic findings. Therefore, true neurologic causes, representing underlying neurovascular disease and not transient autonomic dysfunction, are rare.",
"      <br/>",
"      <br/>",
"      Examples of neurologic syncope include: subarachnoid hemorrhage, transient ischemic attack, subclavian steal syndrome, and complex migraine headache. Stroke and transient ischemic attacks generally cause focal neurologic deficits that do not recover rapidly or completely. Often, patients with cerebrovascular disease convey a history of nonsyncopal episodes featuring neurologic deficits. Syncope may be misconstrued as seizure because many patients with transient loss of consciousness have brief convulsive episodes, particularly if bystanders or objects keep them upright. Syncope can usually be differentiated from seizure by the brevity of the convulsions and the lack a true postictal phase. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"       \"Pathogenesis and etiology of syncope\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Psychiatric syncope &ndash; Anxiety and panic disorders can cause situational syncope. Emergency clinicians must be cautious when attributing syncope to psychiatric causes. Patients with hypoxia, inadequate cerebral perfusion, or other medical conditions may appear confused or anxious. Patients with psychiatric syncope are generally young, without cardiac disease, and complain of multiple episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Drug induced loss of consciousness &ndash; Drugs of abuse and alcohol may cause a transient loss of consciousness, but generally these patients manifest signs of toxicity, and do not spontaneously return to normal neurologic function immediately after regaining consciousness. Alcohol can also cause symptomatic orthostasis by impairing vasoconstriction [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Metabolic &ndash; Metabolic causes of syncope include hypoglycemia and hypoxia.",
"     </li>",
"     <li>",
"      Rare causes &ndash; Rare causes of syncope include atrial myxoma, Takayasu's arteritis, systemic mastocytosis, and carcinoid. Anaphylaxis can involve syncope and loss of consciousness, and both patients and witnesses sometimes overlook or forget the more subtle, earlier symptoms, such as flushing, itching, hives, cough, bronchospasm, or abdominal cramping. In addition, these less dramatic symptoms may have resolved by the time the patient is evaluated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"       \"Anaphylaxis: Rapid recognition and treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history is essential to determine accurately the underlying cause of syncope. Several studies suggest that history and physical examination lead to the diagnosis in approximately half of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Other studies have assessed specific signs and symptoms to determine which patients are at increased risk for serious outcomes, particularly sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/9,19-22\">",
"     9,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &ndash; Young patients more often experience neurocardiogenic syncope. Nevertheless, the emergency clinician must consider the possibility of dysrhythmia, particularly if other concerning factors exist (eg, exertional syncope, family history of sudden death). Electrocardiogram findings consistent with dysrhythmia include a short or prolonged QTc or short PR interval.",
"      <br/>",
"      <br/>",
"      Elderly patients appear to be at greater risk for adverse outcomes following syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/23\">",
"       23",
"      </a>",
"      ]. Elderly patients are more likely to have autonomic dysfunction, orthostasis, and multiple medications, increasing the risk for syncope. Several studies, however, suggest that while age correlates with death and other adverse outcomes, it is nonspecific and a history of underlying heart disease is more predictive [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/24\">",
"       24",
"      </a>",
"      ]. One prospective observational study of 45 consecutive patients 50 years and older with syncope found no significant events at one month in patients whose emergency department evaluation was unremarkable [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/25\">",
"       25",
"      </a>",
"      ].The use of a number of different age thresholds to define \"elderly\" makes it difficult to interpret the data. One study used 45 years as a cutoff, another 75 years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/9\">",
"       9",
"      </a>",
"      ], while consensus opinions have used 60 or 70 years [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/6,26\">",
"       6,26",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      We feel there is little utility in using any specific age threshold for increased risk when assessing patients with syncope. Risk of adverse outcomes after syncope gradually increases with age, and should be considered in the context of other risk factors, particularly heart disease.",
"     </li>",
"     <li>",
"      Associated symptoms and triggers &ndash; Concomitant symptoms can provide important diagnostic clues. As an example, chest pain may indicate an acute coronary syndrome or pulmonary embolism. Palpitations suggest an arrhythmia. Dyspnea raises concern for pulmonary embolism or heart failure. Headache raises the possibility of subarachnoid hemorrhage. Symptoms such as headache, paresthesias, or weakness may suggest a neurologic cause.",
"      <br/>",
"      <br/>",
"      The emergency clinician should seek a history consistent with neurocardiogenic syncope, as these patients are low risk. A prodrome generally precedes neurocardiogenic syncope, and often includes a sense of warmth, nausea and vomiting, diaphoresis, and pallor, either just prior to or shortly after the event. Inquiring about potential neurocardiogenic triggers is also helpful. Triggers commonly associated with neurocardiogenic syncope include strong physical or emotional stress, micturition, defecation, coughing, swallowing, and prolonged standing in a warm environment.",
"     </li>",
"     <li>",
"      Position &ndash; Patients who lose consciousness with prolonged standing (ie, minimum of 15 to 20 minutes) are more likely to have neurocardiogenic syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/23\">",
"       23",
"      </a>",
"      ]. Patients who lose consciousness while moving from a lying to a standing position are more likely to have orthostasis. Syncope while sitting or supine is suspicious for arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/23,27\">",
"       23,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Onset &ndash; Sudden loss of consciousness without warning or prodrome suggests arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/23\">",
"       23",
"      </a>",
"      ]. A prospective observational study of patients with recurrent syncope, provided with an implantable loop recorder, found that 64 percent of patients sustained an arrhythmia at the time of their sudden loss of consciousness [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/28\">",
"       28",
"      </a>",
"      ]. Patients with prodromes are more likely to have neurocardiogenic syncope and have repeatedly been shown to be low risk [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Duration of symptoms &ndash; The duration of a syncopal event is difficult to quantify. Patients are generally unaware of the duration of their loss of unconsciousness and events are often unwitnessed or poorly quantified if they are witnessed. As a rough guide, an \"event\" or loss of consciousness persisting for more than four or five minutes should raise concerns for seizure or other causes of altered mental status.",
"     </li>",
"     <li>",
"      Exertional syncope &ndash; Syncope with exertion raises the possibility of arrhythmia or cardiac outflow obstruction (eg, aortic stenosis, hypertrophic cardiomyopathy, or pericardial tamponade). These patients warrant a thorough cardiac evaluation, including chest x-ray, electrocardiogram and echocardiography.",
"     </li>",
"     <li>",
"      Seizure versus syncope &ndash; Often clinicians have difficulty determining whether their patient suffered a seizure or syncope. Patients with certain seizure disorders do not manifest generalized convulsions; patients with syncope may have brief",
"      <span class=\"nowrap\">",
"       tonic/clonic",
"      </span>",
"      episodes. Approximately 5 to 15 percent of patients thought to have syncope have a seizure disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/29\">",
"       29",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Factors suggestive of seizure include [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/29,30\">",
"       29,30",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prodrome (aura) different from that described for vasodepressor syncope",
"     </li>",
"     <li>",
"      Episode of abrupt onset associated with injury",
"     </li>",
"     <li>",
"      Presence of a tonic phase before the onset of rhythmic clonic activity",
"     </li>",
"     <li>",
"      Head deviation or unusual posturing during the episode",
"     </li>",
"     <li>",
"      Tongue biting (particularly involving the lateral aspect of the tongue)",
"     </li>",
"     <li>",
"      Loss of bladder or bowel control",
"     </li>",
"     <li>",
"      Prolonged post event (postictal) phase during which the patient is confused and disoriented.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these guidelines, the differentiation of seizures from syncope can be difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications &ndash; A review of the patient's medications may reveal the cause of syncope. This is particularly important with elderly patients. Medications often implicated include calcium channel blockers, beta blockers, alpha blockers, nitrates, antiarrhythmics, diuretics (affecting volume status and electrolyte concentrations), and medications affecting the QTc interval (eg, antipsychotics and antiemetics) (",
"      <a class=\"graphic graphic_table graphicRef62074 \" href=\"UTD.htm?42/56/43915\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Prior episodes &ndash; A history of syncopal episodes may be of value. A single episode or multiple episodes over many years suggests a benign etiology. Several episodes over a short period of time in someone with no history of syncope suggest a more significant cause, such as dysrhythmia.",
"     </li>",
"     <li>",
"      Family history &ndash; A family history of unexplained sudden death or early cardiovascular disease (ie, in close relatives less than 50 years old) places patients at increased risk for cardiac syncope [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Associated injury &ndash; Acute loss of consciousness may result in significant injury or events that predispose to injury. Motor vehicle accidents, hip fractures, and subdural hematomas can result. Emergency clinicians should assess the patient for potential injuries. Although patients with prodromal symptoms have less risk of death and other adverse outcomes following syncope, there is no evidence they have less risk of acute injury from syncope (eg, from falls). Such patients may ignore warning signs and may be just as likely to incur injury as patients without a prodrome [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical exam should focus on vital signs and a focused cardiac and neurologic exam, as well as any specific complaints.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vital signs &ndash; Transient hypotension or bradycardia occur during most syncopal events. Abnormal vital signs generally normalize by the time of evaluation in the emergency department (ED). Persistently abnormal vital signs are concerning and must be investigated. Discrepancies between upper extremities in pulse or blood pressure may reflect aortic dissection or subclavian steal syndrome, and should be investigated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=see_link&amp;anchor=H7#H7\">",
"       \"Subclavian steal syndrome\", section on 'Physical examination'",
"      </a>",
"      .) Low patient oxygen saturation or tachypnea may be a sign of heart failure or pulmonary embolism.",
"      <br/>",
"      <br/>",
"      Orthostatic vital signs should be obtained. The patient should be supine for five minutes before the initial set is obtained. Vital signs are retaken after the patient has been standing for three minutes and compared with initial measurements. The following changes are considered abnormal and may reflect hypovolemia or autonomic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/13\">",
"       13",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Drop in systolic blood pressure of 20 mmHg or more",
"     </li>",
"     <li>",
"      Increase in heart rate of 20 beats per minute or more",
"      <br/>",
"      <br/>",
"      Many asymptomatic patients meet these criteria for orthostasis, but a drop of blood pressure below 90 mmHg associated with symptoms can be diagnostic. Clinicians should keep in mind that syncope from orthostatic hypotension is a diagnosis of exclusion in the emergency department, reserved for low risk patients who have symptoms consistent with the diagnosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Common conditions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac exam &ndash; Auscultation of the heart may reveal a rate that is either abnormal or irregular (eg, atrial fibrillation). The clinician should listen for murmurs, specifically for aortic and mitral stenosis. Extra heart sounds, either an S3 or S4, can often be heard in patients with heart failure. Findings on cardiac exam suggesting structural heart disease should be investigated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"       \"Auscultation of heart sounds\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lung exam &ndash; Auscultation of the lungs may reveal abnormal sounds (eg, crackles, wheezes) consistent with heart failure or other pathology (eg, pulmonary embolus, cardiac ischemia).",
"     </li>",
"     <li>",
"      Neurologic exam &ndash; Patients with syncope by definition return to baseline neurologic function. A thorough exam should be done to identify any subtle focal abnormality suggestive of stroke. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=see_link\">",
"       \"The detailed neurologic examination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neck exam &ndash; Clinicians should listen for a carotid bruit. Murmurs of aortic stenosis may also radiate to the neck. Examine the neck for elevated jugular venous pressure, a possible sign of heart failure.",
"      <br/>",
"      <br/>",
"      Some groups suggest that carotid massage be performed as part of the evaluation of syncope. We feel this test lacks sufficient sensitivity and specificity to play a meaningful diagnostic role in the emergency department. We advise caution when considering whether to perform carotid massage in patients with potential carotid artery disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=see_link\">",
"       \"Reflex syncope\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=see_link&amp;anchor=H4#H4\">",
"       \"Vagal maneuvers\", section on 'Carotid sinus massage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Rectal examination &ndash; A rectal exam with a stool guaiac test can identify some patients with gastrointestinal hemorrhage, which may present with syncope.",
"     </li>",
"     <li>",
"      Intraoral exam &ndash; Lacerations to the lateral aspect of the tongue are suggestive of seizure [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injury assessment and general examination &ndash; The emergency clinician should perform a head to toe exam (ie, secondary survey) looking for evidence of trauma. Common injuries associated with falls following syncope include facial fractures, hips fractures, wrist fractures, and subdural hematomas. A general examination, guided by patient complaints, may reveal important findings, such as papilledema or a pulsatile abdominal mass.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANCILLARY STUDIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several practice guidelines suggest that all patients presenting with syncope receive an electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/6,33\">",
"     6,33",
"    </a>",
"    ]. Though the diagnostic yield of the ECG is low (approximately 2 to 7 percent reveal a significant abnormality), the test is inexpensive and easy to perform, and an abnormal ECG suggests an underlying cardiac problem, which should be investigated further.",
"   </p>",
"   <p>",
"    The clinician should assess the ECG looking for evidence of cardiac arrhythmia or ischemia as the cause of syncope. Some variation exists about what constitutes significant ECG findings. In one prospective observational study, patients with an ECG showing sinus rhythm and no new abnormal morphologic changes compared with prior ECG's had substantially lower risk of adverse events during the week following their syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/9\">",
"     9",
"    </a>",
"    ]. According to a subsequent prospective study by the same research team, high risk findings associated with adverse cardiac outcomes include any nonsinus rhythm identified from any source (ie, standard 12 lead ECG or cardiac monitor tracings obtained in the ambulance or the ED) and any abnormal conduction of the left bundle (ie, left bundle branch block, left anterior or posterior fascicular block, prolonged QRS duration) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/34\">",
"     34",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A consensus group from the European Society of Cardiology lists several factors thought to be suggestive of arrhythmia-induced syncope (",
"    <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/35\">",
"     35",
"    </a>",
"    ]. Significant findings include: prolonged intervals (QRS, QTc), severe bradycardia, preexcitation, and evidence of myocardial infarction. Other notable findings include low voltage in the standard limb leads, suggesting pericardial effusion, and abnormal conduction syndromes (eg, Wolf-Parkinson-White and Brugada). A short QT interval has also been associated with significant arrhythmias that could result in syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link&amp;anchor=H25#H25\">",
"     \"Evaluation of syncope in adults\", section on 'Electrocardiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Cardiac monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;While in the ED, patients suspicious for abnormal cardiac rhythms should be placed on a cardiac monitor. In one prospective observational study of 95 consecutive syncope patients, major abnormalities identified by Holter monitoring included significant bradycardia (heart rate &lt;30",
"    <span class=\"nowrap\">",
"     beats/minute),",
"    </span>",
"    sinus pauses (particularly those &gt;2 seconds), Mobitz II block, complete heart block, ventricular tachycardia, and frequent premature ventricular contractions (PVC's) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/37\">",
"     37",
"    </a>",
"    ]. Such findings alert the clinician to an arrhythmogenic cause of syncope. Atrial tachydysrhythmias may cause a syncopal event, but usually do not in patients with structurally normal hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine laboratory screening in patients with syncope is not supported by evidence and seldom aids in management [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/4,39,40\">",
"     4,39,40",
"    </a>",
"    ]. Hypoglycemia may rarely explain an acute syncopal event, but should be performed on all patients with altered mental status. Clinicians should obtain other tests based on clinical circumstance.",
"   </p>",
"   <p>",
"    Electrolytes may be beneficial in critically ill patients or patients thought to have electrolyte abnormalities from volume loss or diuretic use. In patients with active bleeding or suspected anemia, a hematocrit should be obtained, and coagulation studies may be useful. A hematocrit less than 30 increases the risk of adverse short-term events in patients with syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/9,41\">",
"     9,41",
"    </a>",
"    ]. A urine pregnancy test should be performed in any female of child-bearing age.",
"   </p>",
"   <p>",
"    BNP or pro-BNP measurements appear to be predictive of those at risk for adverse outcomes following syncope. One prospective observational study found that a BNP &gt;300",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    in the setting of syncope is associated with increased risk, but whether this ads value beyond a history of heart failure or structural heart disease remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neurologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history or physical exam suspicious for a transient ischemic attack, stroke, or new onset seizure need further evaluation. Patients without historical or examination features suggestive of neurologic disease need no further neurologic studies. Despite the low diagnostic yield of brain imaging, clinicians overutilize head CT and magnetic resonance imaging (MRI) in the evaluation of syncope patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/40,45\">",
"     40,45",
"    </a>",
"    ]. An electroencephalogram may be useful in ruling out epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not readily available in many emergency departments, echocardiography is helpful in determining the presence of structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/47\">",
"     47",
"    </a>",
"    ]. Echocardiography can show valvular anomalies, wall motion abnormalities, elevated pulmonary pressure (seen with pulmonary embolism), and pericardial effusions. It is most useful in patients with a history of cardiac disease or abnormal electrocardiogram findings.",
"   </p>",
"   <p>",
"    Emergency clinicians are becoming more proficient with limited bedside echocardiography, but its value in the patient with syncope is unclear. History appears to be as valuable a screening tool in determining risk and the need for further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important tasks for the emergency clinician faced with a syncope patient are to identify and manage life-threatening problems and to differentiate among patients safe for discharge and those who require emergent investigation and in-hospital management. In making such determinations, clinicians should consider presyncope (ie, near loss of consciousness) and true syncope a spectrum of the same disease process, with no difference in management [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/5\">",
"     5",
"    </a>",
"    ]. An algorithm outlining emergency department management (",
"    <a class=\"graphic graphic_algorithm graphicRef69774 \" href=\"UTD.htm?35/30/36320\">",
"     algorithm 1",
"    </a>",
"    ) and a table listing dangerous causes of syncope (",
"    <a class=\"graphic graphic_table graphicRef81820 \" href=\"UTD.htm?6/36/6732\">",
"     table 1",
"    </a>",
"    ) are provided.",
"   </p>",
"   <p>",
"    Determining the cause of syncope in patients presenting to the emergency department (ED) is difficult [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/41\">",
"     41",
"    </a>",
"    ]. Using a careful history, physical examination, and an electrocardiogram (ECG), along with selective ancillary testing, clinicians can identify the cause in approximately 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Even with intensive inpatient and outpatient testing (eg, loop recorders, Holter monitors, tilt table testing, and electrophysiology studies), clinicians remain unable to determine the cause of syncope in 25 to 40 percent of patients.",
"   </p>",
"   <p>",
"    When evaluating the syncope patient, emergency clinicians should keep in mind three questions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Is this true syncope or does some other serious condition account for the patient's loss of consciousness (eg, stroke, seizure, head injury)?",
"     </li>",
"     <li>",
"      If this is true syncope, is there a clear life-threatening cause?",
"     </li>",
"     <li>",
"      If this is true syncope and the cause is not clear, is the patient at high risk?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Life-threatening causes of syncope include: hemorrhage (eg, gastrointestinal, subarachnoid), pulmonary embolism, and cardiac syncope from arrhythmia or acute coronary syndrome.",
"   </p>",
"   <p>",
"    Patients with syncope from major hemorrhage usually have a low hematocrit. This may not be the case if bleeding is severe and acute, in which case the hematocrit can be misleading. Gastrointestinal bleeding is the most common cause, and often the rectal exam or a stool guaiac test will be positive for blood. The emergency clinician must consider other sources of hemorrhage, including: ruptured aortic aneurysm, ruptured ectopic pregnancy, ruptured ovarian cyst, and ruptured spleen. Appropriate diagnostic testing should be performed. Obtain a quantitative pregnancy test in all women of child-bearing age. Bedside ultrasound can be invaluable in determining the presence of abdominal aortic aneurysm, ectopic pregnancy, and intraabdominal blood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link\">",
"     \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=see_link\">",
"     \"Ultrasonography of pregnancy of unknown location\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=see_link\">",
"     \"Evaluation and management of ruptured ovarian cyst\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pulmonary embolism (PE) is an uncommon but potentially dangerous cause of syncope. Patients with pulmonary embolism often present with dyspnea and chest pain, and may be hypoxic. An electrocardiogram (ECG) with evidence of right heart strain is suggestive. Most often the diagnosis is made by helical CT scan. When suspecting PE, clinicians should perform a work-up based on the patient's baseline risk. Evaluation and management of pulmonary embolus are discussed elsewhere. Patients whose presenting symptom of pulmonary embolism is syncope are not at increased risk of death compared with other patients with pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Syncope associated with a significant headache suggests possible subarachnoid hemorrhage, and evaluation with head CT and lumbar puncture may be necessary. Should historical features or examination findings suggest transient ischemic attack or stroke, clinicians should obtain a CT with angiography or MRI, and neurologic consultation. Suspected seizure should be evaluated with neuroimaging (head CT or MRI) and electroencephalogram (EEG), as an in-patient or out-patient. A less extensive evaluation may be appropriate for patients with an established seizure diagnosis and no concerning features in their presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Diagnosing cardiac syncope is especially important because the one-year mortality of such patients approaches 30 percent, significantly higher than noncardiac syncope or syncope of unknown etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/2\">",
"     2",
"    </a>",
"    ]. The mortality of syncope patients with heart failure is even higher [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/10\">",
"     10",
"    </a>",
"    ]. We suggest clinicians obtain an ECG in all syncope patients. The emergency clinician should study the ECG for evidence of ischemia, arrhythmia, and conduction abnormalities. An abnormal ECG or concerning history should prompt further workup, including echocardiography. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Electrocardiogram'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link&amp;anchor=H25#H25\">",
"     \"Evaluation of syncope in adults\", section on 'Electrocardiogram'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Arrhythmia is the most common cause of cardiac syncope, but may not manifest during the course of an ED evaluation. Syncope patients should be placed on a cardiac monitor while evaluated in the ED. Myocardial infarction (MI) is a rare but important cause of syncope. Most such patients have atypical presentations without ST segment elevations on initial ECG's. MI occurs in about 3 percent of patients with syncope and the negative predictive value of a \"normal\" ECG is greater than 99 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several historical factors raise concern for cardiac syncope, including: a strong family history (eg, close relative with sudden death or MI before 50 years old), a history of heart disease (eg, heart failure, MI, valvular disease, arrhythmia), and symptoms consistent with heart disease (eg, chest pain, palpitations, shortness of breath).",
"   </p>",
"   <p>",
"    Examination findings suggestive of cardiac syncope include abnormal vital signs, including orthostatic changes and discrepant pulses or blood pressure, and abnormal heart sounds. If history or physical examination suggests structural heart disease, an echocardiogram should be obtained. Review the patient's medication list for drugs that may affect the heart rate or rhythm or blood pressure. The elderly and patients taking multiple medications are at greater risk of syncope from medication effects [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Physical examination'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'History'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients diagnosed with neurocardiogenic (vasovagal) syncope are at very low risk of adverse outcomes. Historical factors, including a prodrome (eg, sense of warmth, dizziness, pallor, diaphoresis, abdominal pain, or nausea), may suggest the diagnosis. Clinicians may be able to identify potential triggers, such as micturition, defecation, cough, prolonged standing, or a stressful event (eg, blood draw). A history suggestive of neurocardiogenic syncope coupled with an unremarkable physical exam and a normal ECG constitute a reassuring presentation, with little risk of life-threatening complications.",
"   </p>",
"   <p>",
"    Despite exhaustive testing, many patients with syncope lack a clear diagnosis. A subset of these patients may have occult cardiac syncope.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency clinicians will be unable to determine a diagnosis in a significant number of patients who present to the emergency department (ED) with syncope. In such instances, using risk stratification to guide management and disposition represents a practical approach. A treatment algorithm is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef69774 \" href=\"UTD.htm?35/30/36320\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Using the risk factors identified in the studies described below can help clinicians determine patient risk and appropriate disposition (",
"    <a class=\"graphic graphic_table graphicRef82033 \" href=\"UTD.htm?9/3/9275\">",
"     table 4",
"    </a>",
"    ). While individual studies may be limited by such factors as the size of the cohort, the number of adverse events, and the definition of an event, a consistent theme emerges: patients with an abnormal ECG on presentation or a history of heart disease, particularly structural heart disease (eg, CHF), are at greater risk for adverse outcomes.",
"   </p>",
"   <p>",
"    Risk stratification tools should be used to assist clinical judgment, but cannot replace it. When applying such tools, clinicians must be careful to include only appropriate patients. Patients with significant underlying pathology and patients who do not reflect the population in which the risk stratification tool was studied are not appropriate subjects. As examples, a syncope patient with associated acute coronary syndrome may not meet any high risk criteria but obviously requires admission, while patients with loss of consciousness from head trauma or illicit drug use cannot be assessed using a decision rule if such patients were excluded from the rule's derivation and validation studies.",
"   </p>",
"   <p>",
"    Several research groups have attempted to identify variables associated with increased risk for short-term and one-year morbidity and mortality following a syncopal episode. According to a systematic review, each approach has limitations and no one decision rule should be used in isolation to determine patient risk or disposition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/51\">",
"     51",
"    </a>",
"    ]. However, several important risk factors have been identified by multiple groups and these should be incorporated into the clinician&rsquo;s assessment. The findings of major research groups are described here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One research group performed derivation and validation studies on cohorts of consecutive ED patients with syncope to identify predictors of arrhythmia and death at one year [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/20\">",
"       20",
"      </a>",
"      ]. Significant risk factors were a history of arrhythmia, an abnormal electrocardiogram (ECG), a history of decompensated (or congestive) heart failure, and age over 45 years.",
"     </li>",
"     <li>",
"      Another research group assessed adverse outcomes at 7 and 30 days in their derivation and validation of The San Francisco Syncope Rule (SFSR) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/9,52,53\">",
"       9,52,53",
"      </a>",
"      ]. Significant predictors of adverse events (primarily arrhythmia) included a history of acute decompensated heart failure (ie, congestive heart failure, CHF), an abnormal ECG (nonsinus rhythm or new changes), a hematocrit of less than 30, a complaint of shortness of breath, and a systolic blood pressure of less than 90 mmHg at triage. &nbsp; &nbsp;",
"      <br/>",
"      <br/>",
"      Further study is needed to determine whether the SFSR can be applied to all ED patient populations. A systematic review of external validation studies of the SFSR found that it is the most thoroughly investigated prediction rule for the assessment of syncope and that validation studies have reported inconsistent results [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/54\">",
"       54",
"      </a>",
"      ]. Such inconsistencies may be due to the use of different definitions for arrhythmia, different definitions for an abnormal ECG, and differences in the clinicians interpreting the tracing [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The OESIL (Osservatorio Epidemiologico sulla Sincope nel Lazio) study group developed a risk score based on predictors of death at one year, which they found to be an abnormal ECG, a history of cardiovascular disease (including heart failure), age over 65, and syncope without prodrome [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other researchers developed and validated a prediction score for subsequent arrhythmia in patients with unexplained syncope following a standard ED evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/22\">",
"       22",
"      </a>",
"      ]. They found the significant variables to be an abnormal ECG, a history of heart failure, and age above 65 years. The prevalence of arrhythmia was nearly identical in each cohort, though each phase of the study was performed in a different country (Switzerland and the United States).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the results of these prospective studies, findings from a number of large retrospective studies further support the importance of structural heart disease as an important risk factor for adverse outcome following syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Emergency Physicians (ACEP) has published evidence-based guidelines on the management and disposition of patients with syncope. This policy statement is based primarily on the risk stratification data presented above and suggests admission for patients with evidence of acute decompensated (ie, congestive) heart failure or structural heart disease and patients at high risk for adverse outcomes (",
"    <a class=\"graphic graphic_table graphicRef82033 \" href=\"UTD.htm?9/3/9275\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/33\">",
"     33",
"    </a>",
"    ]. The American College of Physicians and European Society of Cardiology have also established guidelines and algorithms for management and disposition [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/6\">",
"     6",
"    </a>",
"    ]. We suggest emergency clinicians use the ACEP guidelines and the attached ED syncope algorithm, which are better suited to the conditions of their practice (",
"    <a class=\"graphic graphic_algorithm graphicRef69774 \" href=\"UTD.htm?35/30/36320\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a study to assess their decision-making, emergency clinicians demonstrated excellent judgment regarding patient risk, but often did not determine disposition based on their judgment, choosing to admit close to 30 percent of patients whom they felt had a less than 2 percent chance of a serious adverse outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/41\">",
"     41",
"    </a>",
"    ]. The researchers concluded that using clinical judgment augmented by risk stratification may reduce hospital admissions and save some of the estimated two billion dollars spent on syncope each year in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PATIENT DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with obvious cardiac or neurologic causes of syncope, as well as those with concerning symptoms or signs, should be investigated thoroughly in the emergency department (ED) and likely admitted for further in-hospital testing or treatment. To some degree, clinician judgment determines which symptoms or signs are \"concerning,&rdquo; but such findings may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Syncope accompanied by chest pain or shortness of breath",
"     </li>",
"     <li>",
"      Exertional syncope",
"     </li>",
"     <li>",
"      Abnormal vital signs",
"     </li>",
"     <li>",
"      Abnormal findings on cardiac, pulmonary, or neurologic examination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For well-appearing asymptomatic patients with an unclear cause, clinicians should determine the risk for adverse outcome. Clinicians determine risk on the basis of patient history, examination and electrocardiogram (ECG) findings, and evidence-based guidelines. The presence of any of the following features determines high risk (",
"    <a class=\"graphic graphic_table graphicRef82033 \" href=\"UTD.htm?9/3/9275\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Risk stratification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal ECG",
"     </li>",
"     <li>",
"      History of structural heart disease or clinical findings suggestive of heart failure",
"     </li>",
"     <li>",
"      Persistently low blood pressure (systolic &lt;90 mmHg)",
"     </li>",
"     <li>",
"      Shortness of breath with event or during evaluation",
"     </li>",
"     <li>",
"      Hematocrit &lt;30 (if obtained)",
"     </li>",
"     <li>",
"      Older age and associated comorbidities",
"     </li>",
"     <li>",
"      Family history of sudden cardiac death",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    High-risk patients should be investigated in the ED and likely admitted. Patients at risk for significant arrhythmias should be admitted to cardiology for pacemaker or automatic implantable defibrillators as indicated. Low risk asymptomatic patients may be discharged, provided out-patient follow-up can be arranged and the clinician has no other concerns. Patients with obvious neurocardiogenic syncope who have returned to baseline and are asymptomatic without injury should be discharged. Outpatient evaluation of syncope, including the use of ambulatory monitors, tilt table testing, and other diagnostic techniques, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=see_link\">",
"     \"Evaluation of syncope in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=see_link\">",
"     \"Pathogenesis and etiology of syncope\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27399?source=see_link\">",
"     \"Upright tilt table testing in the evaluation of syncope\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some emergency departments, patients identified as intermediate risk are managed in a syncope observation unit. In one observational study, 103 consecutive patients presenting to an emergency department with syncope were randomly assigned to standard care or care in a syncope observation unit [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients in the observation unit required fewer admissions and no significant differences in mortality or recurrent syncope were detected. Further studies are needed to determine if such units provide a cost benefit, without missing significant outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;One prospective randomized multicenter study found that instructing patients diagnosed with vasovagal syncope in the use of physical counterpressure maneuvers (PCM) decreased the incidence of recurrent episodes of syncope from 51 percent to 32 percent, compared with conventional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/52/9034/abstract/57\">",
"     57",
"    </a>",
"    ]. Conventional therapy consisted of explaining the mechanism underlying fainting and providing advice about lifestyle modifications (eg, avoiding known triggers, increasing fluid and salt intake, lying down when symptoms occur). PCM consisted of one or more of the following: (1) leg crossing combined with tensing of the muscles of the legs, abdomen, and buttocks; (2) arm tensing by grasping one hand with the other and forcibly abducting the arms; or (3) squeezing an object clasped in the dominant hand.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When evaluating the patient with syncope, the primary responsibility of the emergency clinician is to assess whether a life-threatening cause is present, and to provide appropriate management and disposition. The most important causes to consider are: cardiac syncope, blood loss, pulmonary embolism, and subarachnoid hemorrhage. Other conditions, such as seizure, stroke, and head injury, do not meet the technical definition of syncope but should be considered during the initial assessment. An algorithm outlining emergency department management (",
"      <a class=\"graphic graphic_algorithm graphicRef69774 \" href=\"UTD.htm?35/30/36320\">",
"       algorithm 1",
"      </a>",
"      ) and a table listing dangerous causes of syncope (",
"      <a class=\"graphic graphic_table graphicRef81820 \" href=\"UTD.htm?6/36/6732\">",
"       table 1",
"      </a>",
"      ) are provided. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Differential diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common but less dangerous causes of syncope include: neurocardiogenic, carotid sinus sensitivity, orthostasis, and medication-related (",
"      <a class=\"graphic graphic_table graphicRef62074 \" href=\"UTD.htm?42/56/43915\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Common conditions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Historical features that reflect increased risk of a dangerous cause of syncope include: concomitant symptoms (eg, shortness of breath, headache, chest pain), sudden loss of consciousness without prodrome, exertional syncope, older age, and family history of sudden death. The clinician should carefully review the patient's medications. Medication reactions account for a significant percentage of syncopal episodes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Syncope and seizure can be difficult to differentiate. Characteristics to help clinicians make this distinction are described in the text. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'History'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perform a careful physical examination focusing on vital signs and the neurologic and cardiac examination. Patients with syncope often fall and sustain secondary injuries, which may include the head (eg, subdural hemorrhage), wrist, or hip. Perform a symptom-guided examination looking for injuries. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Obtain an electrocardiogram (ECG) on all syncope patients. Significant findings include: prolonged intervals (QRS, QTc), severe bradycardia, preexcitation, and evidence of myocardial infarction (",
"      <a class=\"graphic graphic_table graphicRef78397 \" href=\"UTD.htm?20/26/20908\">",
"       table 3",
"      </a>",
"      ). Other notable findings include low voltage in the standard limb leads, suggesting pericardial effusion, and abnormal conduction syndromes (eg, Wolf-Parkinson-White, Brugada, and short QT syndromes). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Electrocardiogram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Emergency clinicians rely on information garnered from the history, examination, and ECG to assess the patient with syncope. While performing their assessment, they should keep in mind three questions (",
"      <a class=\"graphic graphic_algorithm graphicRef69774 \" href=\"UTD.htm?35/30/36320\">",
"       algorithm 1",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Is this true syncope or does some other serious condition account for the patient's loss of consciousness (eg, stroke, seizure, head injury)?",
"     </li>",
"     <li>",
"      If this is true syncope, is there a clear life-threatening cause?",
"     </li>",
"     <li>",
"      If this is true syncope and the cause is not clear, is the patient at high risk? (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Approach to diagnosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with obvious cardiac or neurologic causes of syncope, as well as those with concerning symptoms or signs, should be investigated thoroughly in the ED and likely admitted. Patients with obvious neurocardiogenic syncope who have returned to baseline and are asymptomatic without injury can be discharged. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Patient disposition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For well-appearing asymptomatic patients with an unclear cause, clinicians should determine the risk for adverse outcome. Clinicians determine risk on the basis of patient history, examination and electrocardiogram (ECG) findings, and evidence-based guidelines. We suggest augmenting clinical judgment with validated decision tools. A composite table of high risk features based on findings from several studies is provided (",
"      <a class=\"graphic graphic_table graphicRef82033 \" href=\"UTD.htm?9/3/9275\">",
"       table 4",
"      </a>",
"      ). High-risk patients should be investigated in the ED and likely admitted. Low risk asymptomatic patients may be discharged, with appropriate outpatient follow-up. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Risk stratification'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Patient disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/1\">",
"      Day SC, Cook EF, Funkenstein H, Goldman L. Evaluation and outcome of emergency room patients with transient loss of consciousness. Am J Med 1982; 73:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/2\">",
"      Kapoor WN, Karpf M, Wieand S, et al. A prospective evaluation and follow-up of patients with syncope. N Engl J Med 1983; 309:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/3\">",
"      Kapoor WN. Evaluation and outcome of patients with syncope. Medicine (Baltimore) 1990; 69:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/4\">",
"      Martin GJ, Adams SL, Martin HG, et al. Prospective evaluation of syncope. Ann Emerg Med 1984; 13:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/5\">",
"      Grossman SA, Babineau M, Burke L, et al. Do outcomes of near syncope parallel syncope? Am J Emerg Med 2012; 30:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/6\">",
"      Linzer M, Yang EH, Estes NA 3rd, et al. Diagnosing syncope. Part 1: Value of history, physical examination, and electrocardiography. Clinical Efficacy Assessment Project of the American College of Physicians. Ann Intern Med 1997; 126:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/7\">",
"      Brignole M, Menozzi C, Bartoletti A, et al. A new management of syncope: prospective systematic guideline-based evaluation of patients referred urgently to general hospitals. Eur Heart J 2006; 27:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/8\">",
"      Farwell DJ, Sulke AN. Does the use of a syncope diagnostic protocol improve the investigation and management of syncope? Heart 2004; 90:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/9\">",
"      Quinn JV, Stiell IG, McDermott DA, et al. Derivation of the San Francisco Syncope Rule to predict patients with short-term serious outcomes. Ann Emerg Med 2004; 43:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/10\">",
"      Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: high risk of sudden death regardless of origin of syncope. J Am Coll Cardiol 1993; 21:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/11\">",
"      Wolfe TR, Allen TL. Syncope as an emergency department presentation of pulmonary embolism. J Emerg Med 1998; 16:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/12\">",
"      Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med 2002; 347:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/13\">",
"      Sarasin FP, Louis-Simonet M, Carballo D, et al. Prevalence of orthostatic hypotension among patients presenting with syncope in the ED. Am J Emerg Med 2002; 20:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/14\">",
"      Baraff LJ, Schriger DL. Orthostatic vital signs: variation with age, specificity, and sensitivity in detecting a 450-mL blood loss. Am J Emerg Med 1992; 10:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/15\">",
"      Koziol-McLain J, Lowenstein SR, Fuller B. Orthostatic vital signs in emergency department patients. Ann Emerg Med 1991; 20:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/16\">",
"      Hanlon JT, Linzer M, MacMillan JP, et al. Syncope and presyncope associated with probable adverse drug reactions. Arch Intern Med 1990; 150:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/17\">",
"      Kapoor WN, Fortunato M, Hanusa BH, Schulberg HC. Psychiatric illnesses in patients with syncope. Am J Med 1995; 99:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/18\">",
"      Narkiewicz K, Cooley RL, Somers VK. Alcohol potentiates orthostatic hypotension : implications for alcohol-related syncope. Circulation 2000; 101:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/19\">",
"      Oh JH, Hanusa BH, Kapoor WN. Do symptoms predict cardiac arrhythmias and mortality in patients with syncope? Arch Intern Med 1999; 159:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/20\">",
"      Martin TP, Hanusa BH, Kapoor WN. Risk stratification of patients with syncope. Ann Emerg Med 1997; 29:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/21\">",
"      Colivicchi F, Ammirati F, Melina D, et al. Development and prospective validation of a risk stratification system for patients with syncope in the emergency department: the OESIL risk score. Eur Heart J 2003; 24:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/22\">",
"      Sarasin FP, Hanusa BH, Perneger T, et al. A risk score to predict arrhythmias in patients with unexplained syncope. Acad Emerg Med 2003; 10:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/23\">",
"      Calkins H, Shyr Y, Frumin H, et al. The value of the clinical history in the differentiation of syncope due to ventricular tachycardia, atrioventricular block, and neurocardiogenic syncope. Am J Med 1995; 98:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/24\">",
"      Kapoor WN, Hanusa BH. Is syncope a risk factor for poor outcomes? Comparison of patients with and without syncope. Am J Med 1996; 100:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/25\">",
"      Morag RM, Murdock LF, Khan ZA, et al. Do patients with a negative Emergency Department evaluation for syncope require hospital admission? J Emerg Med 2004; 27:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/26\">",
"      American College of Emergency Physicians. Clinical policy: critical issues in the evaluation and management of patients presenting with syncope. Ann Emerg Med 2001; 37:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/27\">",
"      Alboni P, Brignole M, Menozzi C, et al. Diagnostic value of history in patients with syncope with or without heart disease. J Am Coll Cardiol 2001; 37:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/28\">",
"      Krahn AD, Klein GJ, Yee R, et al. Predictive value of presyncope in patients monitored for assessment of syncope. Am Heart J 2001; 141:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/29\">",
"      Sheldon R, Rose S, Ritchie D, et al. Historical criteria that distinguish syncope from seizures. J Am Coll Cardiol 2002; 40:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/30\">",
"      Benbadis SR, Wolgamuth BR, Goren H, et al. Value of tongue biting in the diagnosis of seizures. Arch Intern Med 1995; 155:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/31\">",
"      Bergfeldt L. Differential diagnosis of cardiogenic syncope and seizure disorders. Heart 2003; 89:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/32\">",
"      Driscoll DJ, Jacobsen SJ, Porter CJ, Wollan PC. Syncope in children and adolescents. J Am Coll Cardiol 1997; 29:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/33\">",
"      Huff JS, Decker WW, Quinn JV, et al. Clinical policy: critical issues in the evaluation and management of adult patients presenting to the emergency department with syncope. Ann Emerg Med 2007; 49:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/34\">",
"      Quinn J, McDermott D. Electrocardiogram findings in emergency department patients with syncope. Acad Emerg Med 2011; 18:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/35\">",
"      Brignole M, Alboni P, Benditt D, et al. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001; 22:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/36\">",
"      Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol 2011; 58:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/37\">",
"      Bass EB, Curtiss EI, Arena VC, et al. The duration of Holter monitoring in patients with syncope. Is 24 hours enough? Arch Intern Med 1990; 150:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/38\">",
"      Brembilla-Perrot B, Beurrier D, de la Chaise AT, et al. Significance and prevalence of inducible atrial tachyarrhythmias in patients undergoing electrophysiologic study for presyncope or syncope. Int J Cardiol 1996; 53:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/39\">",
"      Eagle KA, Black HR. The impact of diagnostic tests in evaluating patients with syncope. Yale J Biol Med 1983; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/40\">",
"      Mendu ML, McAvay G, Lampert R, et al. Yield of diagnostic tests in evaluating syncopal episodes in older patients. Arch Intern Med 2009; 169:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/41\">",
"      Quinn JV, Stiell IG, McDermott DA, et al. The San Francisco Syncope Rule vs physician judgment and decision making. Am J Emerg Med 2005; 23:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/42\">",
"      Reed MJ, Newby DE, Coull AJ, et al. The ROSE (risk stratification of syncope in the emergency department) study. J Am Coll Cardiol 2010; 55:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/43\">",
"      Costantino G, Solbiati M, Pisano G, Furlan R. NT-pro-BNP for differential diagnosis in patients with syncope. Int J Cardiol 2009; 137:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/44\">",
"      Reed MJ, Newby DE, Coull AJ, et al. Role of brain natriuretic peptide (BNP) in risk stratification of adult syncope. Emerg Med J 2007; 24:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/45\">",
"      Pires LA, Ganji JR, Jarandila R, Steele R. Diagnostic patterns and temporal trends in the evaluation of adult patients hospitalized with syncope. Arch Intern Med 2001; 161:1889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/46\">",
"      Zaidi A, Clough P, Cooper P, et al. Misdiagnosis of epilepsy: many seizure-like attacks have a cardiovascular cause. J Am Coll Cardiol 2000; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/47\">",
"      Sarasin FP, Junod AF, Carballo D, et al. Role of echocardiography in the evaluation of syncope: a prospective study. Heart 2002; 88:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/48\">",
"      Jim&eacute;nez D, D&iacute;az G, Valle M, et al. [Prognostic value of syncope in the presentation of pulmonary embolism]. Arch Bronconeumol 2005; 41:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/49\">",
"      Calvo-Romero JM, P&eacute;rez-Miranda M, Bureo-Dacal P. Syncope in acute pulmonary embolism. Eur J Emerg Med 2004; 11:208.",
"     </a>",
"    </li>",
"    <li>",
"     Authors' unpublished data.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/51\">",
"      Serrano LA, Hess EP, Bellolio MF, et al. Accuracy and quality of clinical decision rules for syncope in the emergency department: a systematic review and meta-analysis. Ann Emerg Med 2010; 56:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/52\">",
"      Quinn J, McDermott D, Stiell I, et al. Prospective validation of the San Francisco Syncope Rule to predict patients with serious outcomes. Ann Emerg Med 2006; 47:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/53\">",
"      Quinn J, McDermott D, Kramer N, et al. Death after emergency department visits for syncope: how common and can it be predicted? Ann Emerg Med 2008; 51:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/54\">",
"      Saccilotto RT, Nickel CH, Bucher HC, et al. San Francisco Syncope Rule to predict short-term serious outcomes: a systematic review. CMAJ 2011; 183:E1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/55\">",
"      Derose SF, Gabayan GZ, Chiu VY, Sun BC. Patterns and preexisting risk factors of 30-day mortality after a primary discharge diagnosis of syncope or near syncope. Acad Emerg Med 2012; 19:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/56\">",
"      Shen WK, Decker WW, Smars PA, et al. Syncope Evaluation in the Emergency Department Study (SEEDS): a multidisciplinary approach to syncope management. Circulation 2004; 110:3636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/52/9034/abstract/57\">",
"      van Dijk N, Quartieri F, Blanc JJ, et al. Effectiveness of physical counterpressure maneuvers in preventing vasovagal syncope: the Physical Counterpressure Manoeuvres Trial (PC-Trial). J Am Coll Cardiol 2006; 48:1652.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 293 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9034=[""].join("\n");
var outline_f8_52_9034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANCILLARY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Cardiac monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neurologic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      RISK STRATIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PATIENT DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/293\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/293|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/30/36320\" title=\"algorithm 1\">",
"      Syncope ED algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/293|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/36/6732\" title=\"table 1\">",
"      Syncope causes dangerous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/56/43915\" title=\"table 2\">",
"      Syncope cause common",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/26/20908\" title=\"table 3\">",
"      Risk stratification for syncope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/3/9275\" title=\"table 4\">",
"      Syncope high risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/22/10598?source=related_link\">",
"      Carotid sinus hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/10/11432?source=related_link\">",
"      Emergent evaluation of syncope in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/40/9863?source=related_link\">",
"      Evaluation and management of ruptured ovarian cyst",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18682?source=related_link\">",
"      Evaluation of syncope in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/54/1898?source=related_link\">",
"      Management of splenic injury in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=related_link\">",
"      Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28855?source=related_link\">",
"      Management of the patient with syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/41/12951?source=related_link\">",
"      Mechanisms, causes, and evaluation of orthostatic and postprandial hypotension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/9/5272?source=related_link\">",
"      Pathogenesis and etiology of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/0/18442?source=related_link\">",
"      Reflex syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/39/36471?source=related_link\">",
"      Subclavian steal syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38377?source=related_link\">",
"      The detailed neurologic examination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/24/34184?source=related_link\">",
"      Ultrasonography of pregnancy of unknown location",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27399?source=related_link\">",
"      Upright tilt table testing in the evaluation of syncope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/46/21224?source=related_link\">",
"      Vagal maneuvers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_52_9035="HCC aflatoxin";
var content_f8_52_9035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relation between hepatocellular carcinoma rate and aflatoxin intake",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Location",
"       </td>",
"       <td class=\"subtitle1\">",
"        HCC rate, per 100,000/yr*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Aflatoxin B intake, ng/kg per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kenya, high altitude",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kenya, low altitude",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thailand",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mozambique",
"       </td>",
"       <td>",
"        17.7",
"       </td>",
"       <td>",
"        131.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on hospitalized patients.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Van Rensburg SJ, Cook-Mozaffari P, van Schalkwyk DJ, et al. Br J Cancer 1985; 51:713.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9035=[""].join("\n");
var outline_f8_52_9035=null;
var title_f8_52_9036="Grading of ERCP complications";
var content_f8_52_9036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Grading system for the major complications of endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic sphincterotomy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild",
"       </td>",
"       <td class=\"subtitle1\">",
"        Moderate",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Pancreatitis",
"        </strong>",
"       </td>",
"       <td>",
"        Amylase at least three times normal at more than 24 hours after the procedure, requiring admission or prolongation of planned admission to two to three days",
"       </td>",
"       <td>",
"        Hospitalization of 4 to 10 days",
"       </td>",
"       <td>",
"        Hospitalization of more than ten days, hemorrhagic pancreatitis, phlegmon or pseudocyst, or intervention (percutaneous drainage or surgery)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bleeding",
"        </strong>",
"       </td>",
"       <td>",
"        Clinical (not just endoscopic) evidence of bleeding, hemoglobin drop &lt;3 g, and no need for transfusion",
"       </td>",
"       <td>",
"        Transfusion (four units or less), no angiographic intervention or surgery",
"       </td>",
"       <td>",
"        Transfusion (five units or more) or intervention (angiographic or surgical)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Cholangitis",
"        </strong>",
"       </td>",
"       <td>",
"        Temperature of &gt;38&deg;C for 24 to 48 hours",
"       </td>",
"       <td>",
"        Febrile or septic illness requiring more than three days of hospital treatment or endoscopic or percutaneous intervention",
"       </td>",
"       <td>",
"        Septic shock or surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Perforation",
"        </strong>",
"       </td>",
"       <td>",
"        Possible, or only very slight leak of fluid or contrast, treatable by fluids and suction for three days or less",
"       </td>",
"       <td>",
"        Any definite perforation treated medically for 4 to 10 days",
"       </td>",
"       <td>",
"        Medical treatment for more than 10 days, or intervention (percutaneous or surgical)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Cotton PB, et al. Endoscopic sphincterotomy complications and their management: An attempt at consensus. Gastrointest Endosc 1991; 37:383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9036=[""].join("\n");
var outline_f8_52_9036=null;
var title_f8_52_9037="Specimen collection methods III";
var content_f8_52_9037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Microbiology specimen handling and collection - III",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Specimen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Method",
"       </td>",
"       <td class=\"subtitle1\">",
"        Volume",
"       </td>",
"       <td class=\"subtitle1\">",
"        Storage temperature*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"       <td class=\"subtitle1\">",
"        See UpToDate topic review",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Lower respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Expectorated sputum",
"       </td>",
"       <td>",
"        Sterile container",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25&deg;C",
"       </td>",
"       <td>",
"        Rinse mouth first, use Gram stain to screen for suitability",
"       </td>",
"       <td>",
"        Sputum cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bronchoscopy fluid",
"       </td>",
"       <td>",
"        Sterile container",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25&deg;C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Sputum cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Upper respiratory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Nasal",
"       </td>",
"       <td>",
"        Insert premoistened swab into nares",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        25&deg;C",
"       </td>",
"       <td>",
"        For detection of nasal carriage of S. aureus or",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place into transport media",
"       </td>",
"       <td>",
"        Group A streptococci only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Nasopharynx",
"       </td>",
"       <td>",
"        Insert calcium alginate",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        25&deg;C",
"       </td>",
"       <td rowspan=\"2\">",
"        Routine swabs may not support growth of some organisms (eg, B. pertussis). Use calcium alginate or dacron/rayon swabs",
"       </td>",
"       <td rowspan=\"2\">",
"        Routine swabs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swab into posterior nasopharynx via nose, inoculate medium at bedside or transport swab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Throat",
"       </td>",
"       <td>",
"        Swab posterior pharynx and tonsils",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25&deg;C",
"       </td>",
"       <td>",
"        Inform laboratory if identification of organisms other than group A beta hemolytic streptococci is indicated (eg, N. gonorrheae)",
"       </td>",
"       <td>",
"        Throat cultures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\" rowspan=\"1\">",
"        Stool",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Routine culture",
"       </td>",
"       <td>",
"        Sterile wide-mouth container or enteric transport system",
"       </td>",
"       <td>",
"        &gt;2 grams",
"       </td>",
"       <td>",
"        4&deg;C (25&deg;C if enteric transport system used)",
"       </td>",
"       <td>",
"        Do not send specimens for routine culture on patients who develop diarrhea after 3 days of hospitalization; only send for C. difficile toxin",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        C. difficile toxin",
"       </td>",
"       <td>",
"        Sterile wide-mouth container",
"       </td>",
"       <td>",
"        &gt;5 mL (soft or liquid)",
"       </td>",
"       <td>",
"        4&deg;C for &le;24h, -20&deg;C for &gt;24h",
"       </td>",
"       <td>",
"        Test of choice for patients who develop diarrhea after if &ge;3 days of hospitalization",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ova and parasite examination",
"       </td>",
"       <td>",
"        Sterile wide-mouth container, or commercial transport system",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25&deg;C in fixative",
"       </td>",
"       <td>",
"        Fresh specimens should be examined immediately; Do not send specimens on patients who develop diarrhea after 3 days of hospitalization",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If immediate processing is not possible.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9037=[""].join("\n");
var outline_f8_52_9037=null;
var title_f8_52_9038="Cr concentration Heart Tx";
var content_f8_52_9038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Serum creatinine concentrations and heart transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 404px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Graph showing the pooled weighted average serum creatinine concentrations (mg/dL) derived from published studies describing the renal function in heart transplant recipients receiving cyclosporine based immunosuppressive therapy. In general, the serum creatinine level increases early after transplantation and then stabilizes over time.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9038=[""].join("\n");
var outline_f8_52_9038=null;
var title_f8_52_9039="Prop gen model peri chondro";
var content_f8_52_9039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F51711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F51711&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Proposed multistep genetic model for peripheral chondrosarcoma development and potential targets for treatment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 475px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrow shows candidate adjuvant treatment strategies based on identification of molecular changes during chondrosarcoma progression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Bov&eacute;e JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2006; 6:599. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_52_9039=[""].join("\n");
var outline_f8_52_9039=null;
